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Abstract 
UPMC Children’s Hospital of Pittsburgh started the Genetic Testing Clinic (GTC) in January 
2018. The GTC is a genetic counseling-only clinic that offers same-day and advance-scheduled 
appointments for referrals from non-genetic providers ordering a genetic test. This clinic is unique 
in that it incorporates utilization management (UM) for the requested genetic test while providing 
comprehensive genetic counseling. After one year and 459 patients, outcomes of the clinic, such 
as test order modifications, family history risk assessment and triage, and genetic test uptake were 
assessed. Upon IRB approval, retrospective chart review of the electronic medical record and 
internal databases were performed for 206 of the GTC patients to obtain detailed outcomes of the 
clinic. Additionally, chart review of genetic testing completed by non-genetics providers prior to 
the GTC’s inception in 2017 was performed for a comparison. Chart review identified 14.6% 
(30/206) of the GTC patients had unrelated family history risk factors, for which a referral to 
cancer genetics or cardiogenetics was provided and 7.3% (15/206) of GTC patients had their test 
modified based upon genetic counselor review. Finally, review of possible results, risks, benefits 
and limitations of genetic testing were discussed and documented routinely for GTC patients. In 
contrast, non-genetics providers often lacked documentation of the informed consent process. 
77/150 (51%) of the non-genetics providers did not document any of the possible types of genetic 
testing results, 67/150 (45%) documented one type of possible genetic testing result; 112/150 
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(75%) did not document any risks, benefits or limitations; and 149/150 (99%) did not document 
the possibility of incidental findings. Genetic counseling is valuable for patients undergoing 
genetic testing; however, not every patient receives genetic counseling. This clinic represents a 
service delivery model that provides genetic counseling and UM for patients who may not have 
otherwise received it. This has public health significance as it improves access to genetic 
counseling services, ensures comprehensive pre- and post- test counseling, and has improved 
insurance authorization approval. 
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1.0  Introduction 
1.1 Background 
Genetic testing is an expanding, highly complex process that accounts for a significant 
portion of healthcare spending (UnitedHealth Center for Health Reform and Modernization, 2012). 
Currently, about 75,000 different genetic tests are available, each with their own nuances (Concert 
Genetics, 2018). Historically, healthcare providers specifically trained in genetics were the 
individuals who ordered genetic testing for their patients; however, there is a workforce shortage 
of trained genetics providers to offer services to all patients who could benefit from an evaluation 
(Billings et al., 2005; Hoskovec et al., 2018). In order to address the workforce shortage issue, as 
well as other barriers to accessing genetic counseling, different service delivery models have been 
implemented, such as telegenetics, group genetic counseling, the use of genetic counseling 
assistants, and other service delivery models, with varying degrees of success (Buchanan et al., 
2015; Buchanan et al., 2016; Calzone et al., 2005; Cohen et al., 2012; Cohen et al., 2013; Gammon 
et al., 2018; Hannig et al., 2014; Hilgart et al., 2012; Kubendran et al., 2017; Ormond et al., 2018; 
Otten et al., 2016; Pirzadeh-Miller et al., 2017; Rothwell et al., 2012; Stoll et al., 2018). However, 
as genetic testing has become more commonplace, wait times for a medical genetics evaluation 
have increased despite the use of different service delivery models, thus an increasing number of 
non-genetics providers are ordering genetic testing (Dickerson et al., 2014; Kotzer et al., 2014; 
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Riley et al., 2015; Suarez et al., 2017). Additionally, the advent of phenotypic-driven panels have 
enabled non-genetics providers to choose and order genetic testing with more ease (Ingles et al., 
2011; Silveira-Moriyama & Paciorkowski, 2018; Vento, 2012). To address the long wait times for 
a medical genetics appointment and ensure that patients are receiving quality genetics care, UPMC 
Children’s Hospital of Pittsburgh (CHP) established the Genetic Testing Clinic (GTC) in January 
2018.  
 The GTC is a genetic counseling-only clinic that offers same-day and advance-scheduled 
appointments for referrals from non-genetics providers ordering a specific genetic test. The GTC 
is not available, however, for medically complex patients requiring an evaluation by a medical 
geneticist. In circumstances where the genetic counselor (GC) identifies the need for a medical 
geneticist, those patients are appropriately triaged. The GTC incorporates utilization management 
(UM) in genetic test selection, so that the most appropriate genetic test is ordered for the patient.  
Genetic testing UM has been studied by some commercial genetic testing laboratories, 
which identified that 8-30% of genetic tests are ordered inappropriately, such as duplicate or 
redundant testing or poor clinical utility based on the presenting indication (Kotzer et al., 2014; C. 
E. Miller et al., 2014). Furthermore, genetic UM efforts have been present in hospital systems 
using send out review, consultative services, and/or formulary review (Dickerson et al., 2014; 
Mathias et al., 2016; Riley et al., 2015; Suarez et al., 2017). However, the assessment of a program 
where UM GCs see patients in an outpatient setting and analyzing those pre- and post-test 
outcomes compared to non-genetics providers has not been performed.  
 The availability and depth of genetic testing is expanding rapidly, and there is a need for 
new genetic professional service delivery models to address this expansion. Additionally, as 
genetic testing becomes more routine, non-genetics providers, who may not be as familiar with 
3 
genetic information and testing nuances, are ordering genetic testing more often. The GTC aims 
to fill a gap between demand for genetic services, while incorporating UM and proper pre-test and 
post-test genetic counseling for patients. While this is a novel service delivery model, it may 
become more commonplace as demand for genetic services increases. This study aims to capture 
the benefits and possible limitations of this service, compared to genetic testing ordered by non-
genetics providers alone. 
1.2 Specific Aims 
1.2.1 Specific Aim 1 
 To assess if the pre-test outcomes of genetic testing, defined as length of time for 
insurance authorization, appropriateness of the test order, documentation of informed consent, 
the extent to which family history is documented, and referrals for unrelated family history, are 
improved using the Genetic Testing Clinic compared to genetic testing ordered by non-
genetics providers by evaluating documentation in the electronic medical record.  
1.2.2 Specific Aim 2 
 To determine if the post-test outcomes of genetic testing, defined as genetic testing 
results, actionable parental testing follow-up, and medical genetics referrals, are improved 
using the Genetic Testing Clinic compared to genetic testing ordered by non-genetics 
providers by evaluating documentation in the electronic medical record. 
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1.2.3 Specific Aim 3 
 To investigate if any of the differences in post- test outcomes between the Genetic 
Testing Clinic and non-genetics providers can be explained by any of the demographics or pre-
test outcomes by performing statistical analyses and regression modeling.  
1.2.4 Specific Aim 4 
 To compare the percentage of genetic testing ordered with a genetic counselor’s 
involvement compared to those ordered by non-genetics providers, from 2017 and 2018 by 
reviewing hospital wide data of genetic test ordering. 
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2.0  Literature Review 
2.1 Genetic Testing and the Healthcare System 
Genetic testing is an expanding, highly complex process that accounts for a significant 
portion of healthcare spending (UnitedHealth Center for Health Reform and Modernization, 2012). 
Approximately eight percent of the United States’ national spending on clinical laboratory services 
was for genetic testing, totaling $5 billion in 2010; this is expected to increase to $15 to $25 billion 
by 2021 (UnitedHealth Center for Health Reform and Modernization, 2012). However, the cost of 
genetic testing to the healthcare system is more than just the laboratory’s charge, as there are 
doctors and genetic counselors (GCs) involved in the patient’s care, potential referrals to other 
healthcare providers, and additional testing or screening based on the results, as well as the burden 
on IT to incorporate genetic testing in the EMR. Despite these costs, appropriate genetic testing 
can provide long-term cost savings to the healthcare system by identifying appropriate 
interventions for patients based on their genetic information instead of the “wait and see” or “trial 
and error” approach, as well as avoiding unnecessary screening and medical tests in individuals 
(Tammimies et al., 2015). For example, women who have a high risk for breast cancer based on 
personal and/or family history are recommended to have more vigilant screening, but if a BRCA 
pathogenic variant is identified, risk-reducing mastectomy and salpingo-oophorectomy is 
recommended, which is more cost effective than traditional radiological screening (Yamauchi et 
al., 2018). Similarly, if an individual with a BRCA pathogenic variant has a sister, but that sister 
tested negative for the variant, she does not have an increased risk for breast cancer and does not 
need increased screening, thus saving healthcare money on inappropriate screening. Appropriate 
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genetic testing can save money and provide better healthcare outcomes in many fields including 
but not limited to prenatal findings, child-onset diseases, cancer risk, and pharmaceutical dosing. 
As the field of genetics continues to grow and more genetic tests are offered, it is imperative to 
ensure proper utilization of genetic testing, both for the care of the patient as well as for the cost 
to the healthcare system.  
2.2 Genetic Counseling 
The National Society of Genetic Counselors (NSGC) defined their practice in 2006 as “the 
process of helping people understand and adapt to the medical, psychological and familial 
implications of genetic contributions to disease. This process integrates the following: 
Interpretation of family and medical histories to assess the chance of disease occurrence or 
recurrence; Education about inheritance, testing, management, prevention, resources and research; 
Counseling to promote informed choices and adaptation to the risk or condition” (Resta et al., 
2006).  
GCs are master’s level trained health care providers, receiving education in genetics, 
psychosocial skills, and clinical experience. Sarah Lawrence College was the first genetic 
counseling training program, with their first students matriculating in the Fall of 1969 (Resta, 
1997). Now, there are 41 genetic counseling programs in the United States, with 404 positions 
available for students to enter a training program in 2018 (Accreditation Council for Genetic 
Counseling, n.d.; National Matching Services Inc, 2018). 
Genetic counseling is a unique field that incorporates both medical and psychosocial 
considerations in each appointment. Typical components of a genetic counseling appointment 
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includes information gathering, establishing or verifying a diagnosis, risk assessment, information 
giving, and psychological counseling and support (Uhlmann et al., 2009). This requires a greater 
amount of time than a typical medical appointment and may illicit more emotion than a patient 
typically experiences in other medical appointments.  
2.2.1 Genetic Counseling Specialties  
When the field was established, GCs had limited options for specializing: either pediatric 
or prenatal genetic counseling, as that was reflective of the genetic tests available (Gilgenkrantz, 
1977). GCs practicing in a pediatric setting typically provide genetic counseling services for 
families with a child with indications such as developmental delay, autism, metabolic disorder, or 
dysmorphic features (National Society of Genetic Counselors, n.d.) Pediatric GCs participate in 
the child’s diagnostic odyssey by explaining genetic tests, helping families understand the 
diagnosis, aiding in medical referrals and support services, and providing recurrence risks 
(National Society of Genetic Counselors, n.d.). GCs practicing in a prenatal setting provide 
services for current or future pregnancies, discussing screening and diagnostic tests for 
chromosomal abnormalities and other genetic conditions, as well as the options of termination, 
adoption, donor gametes, and in vitro fertilization (National Society of Genetic Counselors, n.d.). 
Referral indications for prenatal genetic counseling can include advanced maternal age, a family 
history of a genetic condition, abnormal screening or ultrasounds, and exposures to teratogens 
(National Society of Genetic Counselors, n.d.). More recently, artificial reproductive technology 
and infertility genetic counseling emerged as a separate, but related specialty (National Society of 
Genetic Counselors, n.d.).  
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A third main area of specialization, cancer genetic counseling, began in the 1980s when 
hereditary cancer syndromes were starting to be well understood, but significantly expanded in the 
mid-1990s with the discovery of the BRCA genes (Le Marec et al., 1986; Ormiston, 1996). GCs 
who focus on providing cancer genetic counseling services aim to provide information to 
individuals and families who are at an increased risk for cancer, explain cancer screening and 
prevention, testing options, and how this can affect the patient’s medical management (National 
Society of Genetic Counselors, n.d.). (National Society of Genetic Counselors, n.d.). 
More recently, laboratory genetic counseling emerged as a predominant specialty in 
genetic counseling (National Society of Genetic Counselors, n.d.). In this service, GCs act as 
liaisons between the genetic testing laboratory and the ordering clinician (Christian et al., 2012; 
Goodenberger et al., 2015; Zetzsche et al., 2014). These counselors can help facilitate genetic 
testing, explain the limitations of the tests, and explain complex results.  
Finally, there are additional specialties within genetic counseling - such as neurogenetics, 
cardiovascular genetics, ophthogenetics, public health genetics, research, etc. (McWalter et al., 
2015; National Society of Genetic Counselors, n.d.). As genetic technologies expand and 
knowledge about genetic contribution to diseases grows, so does the scope of and need for genetic 
counseling. It is a dynamic field that continues to expand and adapt to meet the needs of the 
community.  
2.2.2 Benefits of Genetic Counseling  
GCs have a unique role in the medical field as they not only understand genetic conditions 
and the nuances of genetic testing, but also understand the psychosocial complexities some of these 
patients may be experiencing through their diagnostic odyssey, grief, or recent diagnosis. Often, 
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the GC can spend more time with their patients to ensure certain goals of a genetics appointment 
are achieved. NSGC conducts an annual professional status survey (PSS) that reported the majority 
(71%) of initial genetic counseling appointments last between 31 and 60 minutes, not including 
prep, follow up, or physician involvement (National Society of Genetic Counselors, 2018). In 
contrast, primary care physicians in the U.S. spend approximately 20 minutes with their patient 
(Irving et al., 2017). In addition to developing a close rapport with their patients, GCs also work 
closely with clinical geneticists and other medical specialists.  
In order to measure genetic counseling outcomes in the patient setting, McAllister el al. 
developed a genetic counseling specific patient reported outcome measure (PROM), a 24-item 
genetic counseling outcome scale (GCOS-24) (McAllister et al., 2011). The study first developed 
an 84-item questionnaire which was completed by 527 members of patient support groups for 
genetic conditions in the United Kingdom. Then, the questionnaire was pared down to 24 items, 
based on rank order of exploratory factor analysis, psychosocial issues specific to genetic 
conditions, and clinical judgement on usefulness. The GCOS-24 was validated by having 395 
patients attending their first genetics appointment complete the survey prior to the appointment 
and two to four weeks after the appointment. This test-retest analysis yielded a genetics specific 
PROM that is validated for analysis of construct of empowerment, shows good internal 
consistency, test–retest reliability, is sensitive to change, and some evidence of construct validity 
(McAllister et al., 2011). Since the GCOS was validated, it has been frequently used in the the 
research process to assess outcomes and benefits to genetic counseling services.  
Comparisons of patient outcomes when genetic testing is ordered with a GC compared to 
a non-genetics provider was performed by Cragun et al. (Cragun et al., 2015). 473 patients 
undergoing BRCA testing were surveyed to see if they recalled receiving pre-test counseling 
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(Cragun et al., 2015). When genetic testing was ordered with a genetic healthcare provider, patients 
were more likely to remember pre-test counseling occurring and recall specific aspects of pre-test 
counseling including: family history assessment, discussing GINA, and receiving a summary letter 
of the appointment (Cragun et al., 2015). Additionally, this study identified that non-genetics 
providers were more likely to order comprehensive BRCA testing when 3-site Ashkenazi Jewish 
testing or single site testing for a known familial variant were more appropriate (Cragun et al., 
2015).  
2.2.3 Workforce Shortage in Genetic Counseling 
While the roles of GCs, and indications to seek a GC are expanding, there is a recognized 
shortage of trained GCs who can provide these needed services (Hoskovec et al., 2018). Currently, 
there are over 4,000 board certified GCs (American Board of Genetic Counseling, n.d.), but a 
workforce supply and demand model, a study of program directors, and anecdotal experiences 
report there is a greater demand for GCs than the number who are currently trained (Hoskovec et 
al., 2018; Pan et al., 2016). In 2015, the Workforce Working Group, comprised of representatives 
of national genetic organizations, was formed in order to quantify the workforce shortage in 
genetic counseling (Hoskovec et al., 2018). In combination with a workforce analysis by 
Dobson|DaVanzo, LLC, a model of supply of GCs and demand for services was created (Hoskovec 
et al., 2018). The workforce supply incorporated assumptions for the number of new genetic 
counseling graduates and those leaving the workforce for retirement or other reasons, while the 
demand was estimated at one fulltime equivalent GC working in direct patient care for 75,000 and 
100,000 people (Hoskovec et al., 2018). At the time of the study in 2017, there was a shortage of 
1,879 GCs in the one GC for every 75,000 people scenario or 791 in the one GC for every 100,000 
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people (Hoskovec et al., 2018). This report predicts an equilibrium will be achieved for supply of 
clinical GCs and demand for services, between 2024 and 2030 (Hoskovec et al., 2018). Some 
clinics are addressing the increased demands for GCs’ services through a variety of unique service 
delivery models (Stoll et al., 2018).  
2.2.4 Barriers to Genetic Counseling 
While genetic counseling is a valuable resource for patients whose genetics may play a key 
role in their health, not all patients are referred for genetic counseling. Not only does the GC 
workforce shortage contribute to barriers to genetic counseling, but non-genetics providers’ 
preparedness for the increased demand for GC services also contributed to these barriers. This was 
noted as early as 2005, when Billings et al. provided workshops and informational meetings about 
genetic services to 600 participants from a variety of healthcare roles (Billings et al., 2005). The 
participants included representatives from insurance companies, medical associations, and chief 
medical officers. They performed qualitative analysis and determined that 90% of participants had 
rudimentary knowledge of genetics and that 95% of participants did not have staff assigned to 
prepare for the influx of genomic medicine. The study also noted that the increase of genetics in 
medical care will warrant new service delivery models throughout medical services. While this 
study was published in 2005, it is worth noting that the study concluded that the medical system 
was not prepared for the increasing use of genomic medicine (Billings et al., 2005).  
Delikurt et al. performed a systematic review of research done on barriers to genetic 
counseling (Delikurt et al., 2015). Of the nine articles reviewed, themes were identified on barriers 
due to non-genetic healthcare providers (“lack of awareness of patient risk factors, failure to obtain 
adequate family history, lack of knowledge of genetics and genetic conditions, lack of awareness 
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of genetic services, inadequate coordination of referral and lack of genetics workforce”) and the 
patients (“lack of awareness of personal risk, lack of knowledge and/or awareness of medical 
history of family members and lack of knowledge of genetic services”) (Delikurt et al., 2015). Of 
these studies reviewed, five were based on cancer genetics, two were based on pediatric genetics 
in Australia, one was based on prenatal genetics in the Netherlands, and one was based on general 
genetics in the U.S.; given the relevance to the present study, the general genetics study from the 
U.S, is reviewed below (Beene-Harris et al., 2007; Delikurt et al., 2015).  
In 2007, five focus groups, consisting of a sickle cell anemia parent support group, a Native 
American student group, parents of children with a birth defect or other special health care needs, 
adults with genetic conditions, and genetics service providers, were performed to assess barriers 
to accessing genetic counseling services and elucidate genetics service needs in the Michigan 
community (Beene-Harris et al., 2007). There were 48 participants in five groups, each consisting 
of five to 15 individuals. The analysis of the focus group transcripts yielded topics similar to 
Delikurt et al, with individual barriers of lack of awareness of risk, lack of knowledge and 
awareness of genetic services or resources, and lack of trust and fear of discrimination identified, 
and institutional barriers of provider lack of knowledge and awareness of genetic services, lack of 
workforce, coordination of care/referral, cost and insurance, and distance from services (Beene-
Harris et al., 2007). 
2.2.5 Access and Service Delivery Models in Genetic Counseling  
NSGC appointed a Service Delivery Model Task Force in 2009 to research various service 
delivery models in genetic counseling. Through discussion and informal literature review, this 
group defined four different types of service delivery for genetic counseling: in-person, telephone, 
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group, and telegenetics (Cohen et al., 2012). In-person refers to the traditional service delivery 
model of a face-to-face appointment between the patient and GC, while the others are newer and 
address certain needs in the profession and patient community. Telephone genetic counseling 
entails conducting the full session (not just results disclosure) over the phone; group genetic 
counseling is when genetic counseling is provided to a group of individuals with the same 
indication (such as advanced maternal age, positive prenatal screening test, or a family history of 
breast cancer); and telegenetics is defined as providing genetic counseling remotely through the 
use of videoconferencing (Cohen et al., 2012). The task force also identified five different types 
of referrals to genetic services: traditional, tandem, triage, rescue, and self. Traditional referrals 
are defined as a referral from a healthcare provider for the GC to provide all the genetic counseling 
and genetic test coordination. Tandem referrals entail a collaborative relationship between a 
healthcare provider and GC, where the healthcare provider orders the genetic testing and performs 
initial genetic counseling, but then refers all patients to the GC for genetic counseling and review 
of results. Triage referrals are similar, with the same collaborative relationship between the 
healthcare provider and GC, but the healthcare provider orders genetic testing and performs initial 
genetic counseling for routine cases, while patients with complex indications or significant family 
history are referred to a GC. Rescue referrals do not entail a collaborative relationship between the 
healthcare provider and GC; instead, they only refer to genetic counseling when there is difficulty. 
Self-referrals are when the patient seeks out genetic counseling themselves instead of from a 
provider referral (Cohen et al., 2012). Finally, the task force specified that a genetics appointment 
can vary based on whether or not the patient meets with the physician or has a physical 
examination, billing practices, and location of appointment (Cohen et al., 2012). While new service 
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delivery models are often defined by their mode of counseling, mode of referral and appointment 
logistics often yield their own unique benefits.  
The task force then surveyed members of NSGC on the use of various service delivery 
models (Cohen et al., 2013). Of the 701 usable responses, an in-person service delivery model was 
used exclusively 54.7% of the time and was “always” or “often” used 95.7% of the time. 45.3 
percent of respondents used multiple service delivery models. Telephone, group, or telegenetics 
was “always” or “often” used 13.4% of the time. Additionally, this study found through the use of 
multiple service delivery models, there was a decrease in patient wait time and a shorter length of 
appointments (Cohen et al., 2013). NSGC’s PSS identified that 59% of GCs provide direct patient 
care, 25% provide non-direct patient care, and 16% provide both. Additionally, of those that 
provide direct patient care for more than 50% of their time, 96% of GCs use in-person service 
delivery, 59% use telephone, 19% use telegenetics, 7% use group genetic counseling, and 65% use 
multiple service delivery models (National Society of Genetic Counselors, 2018).  
2.2.5.1 Telegenetics 
One of the first innovative service delivery models in genetic counseling was the use of 
telemedicine. Telemedicine is broadly defined as credentialed specialists providing remote care to 
medically underserved populations (Field, 1996). Applying both video and audio to clinical 
genetics or genetic counseling is considered telegenetics (Otten et al., 2016). The primary aim of 
telegenetics is to provide services to rural populations, but studies have found it to also be more 
cost-efficient for both patients and providers compared to in-person genetic counseling and help 
meet the increasing demand for genetic counseling services (Buchanan et al., 2015; Buchanan et 
al., 2016; Hilgart et al., 2012; Otten et al., 2016). Hilgart et al. performed a systematic review of 
telegenetics studies and found that all studies reported high or comparable satisfaction to in-person 
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appointments, and while not formally studied, telegenetics yielded cost savings to the clinic and 
patient, as long as telemedicine equipment was already available (Hilgart et al., 2012). A study in 
the Netherlands surveyed ten GCs who practiced in cancer genetics, cardiovascular genetics, and 
urgent prenatal genetics about their experience with telegenetics where the patients use a webcam 
from their home (Otten et al., 2016). This study identified that telegenetics reduces appointment 
time by eight percent and cost by 10 to 12%, but drawbacks of this service delivery model include 
insufficient non-verbal communication and technical issues (Otten et al., 2016). Buchanan et al. 
performed an RCT of 162 patients in rural locations to either receive in-person cancer genetic 
counseling at the academic medical center or video conferenced genetic counseling at a local clinic 
(Buchanan et al., 2015). This study identified that patient satisfaction between the two groups were 
similar, the telegenetics appointment cost on average $106 compared to $244 for in-person, but 
there was a higher no-show rate with telegenetics (11% for in-person compared to 21% for 
telegenetics) (Buchanan et al., 2015). For in-person genetic counseling, the cost for each visit was 
determined by the GC’s travel costs, while the telegenetics cost was determined by the training 
time, clinical costs at the hosting site, and the telegenetics system (Buchanan et al., 2015).  
2.2.5.2 Telephone Genetic Counseling 
While GCs often perform intake or disclose results over the phone, full telephone genetic 
counseling sessions are not as common, given the opportunity of telegenetics. However, outcomes 
of telephone genetic counseling have been studied for both prenatal and cancer indications. Sangha 
et al. assessed knowledge and anxiety differences in women who received telephone genetic 
counseling compared to in-person genetic counseling for abnormal maternal serum screening 
(Sangha et al., 2003). Patients were able to select if they wanted in-person or telephone genetic 
counseling (an RCT failed to elicit participants), were screened for anxiety at the beginning of the 
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appointment, and then mailed a questionnaire eliciting anxiety and knowledge approximately two 
weeks after the appointment. This study had low power, with only 12 patients in each group 
completing the questionnaire, but both had similar knowledge scores (mean 8.3 correct answers 
out of 9 questions for both groups) and anxiety (mean 17.7/40 for the telephone group, mean 20/40 
for the in-person group, with higher scores representing higher anxiety) (Sangha et al., 2003).  
Telephone genetic counseling was also assessed by Schwartz et al. for women diagnosed 
with breast cancer who had a high risk of a BRCA mutation (M. D. Schwartz et al., 2014). In this 
multi-center, RCT, 335 patients had telephone genetic counseling (where a visual aid booklet was 
mailed to them prior to the appointment) and 334 patients had in-person genetic counseling. 
Genetic counseling outcomes, including knowledge, decisional conflict, cancer stress, perceived 
stress, general counseling satisfaction, physical function, and mental function was assessed at 
baseline, two weeks after genetic counseling, and three months after genetic counseling via 
telephone interviews using standardized questionnaires. The study found that telephone genetic 
counseling was noninferior in all domains (M. D. Schwartz et al., 2014). Additionally, the study 
performed a cost savings analysis that yielded a $59 cost savings per patient (shared by the patient 
and clinic) based on no patient travel costs and decreased time in the appointment (M. D. Schwartz 
et al., 2014). A follow-up analysis of the same participants and interview questionnaire responses 
was performed by Peshkin et al. to assess patient perceptions of telephone genetic counseling 
(Peshkin et al., 2016). While there was no difference in satisfaction, telephone patients found the 
appointment more convenient, but felt less support and emotional recognition (Peshkin et al., 
2016).  
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2.2.5.3 Group Genetic Counseling 
Group genetic counseling has been implemented and studied in prenatal and cancer genetic 
counseling. Gammon et al. studied the use of group genetic counseling in a prenatal setting for 
noninvasive prenatal screening, first trimester screening, quad screening, and carrier screening 
(Gammon et al., 2018). The groups, consisting of two to five patients, first had the group genetic 
counseling session, followed by a five to ten minute individual meeting with the GC to discuss 
personal or family history concerns and thoughts about testing. This study used a test-retest 
methodology instead of comparing and found that of the 109 patients, the majority found the group 
session more useful than expected, patients were more prepared to make a decision regarding 
testing, and performed better on knowledge assessments about screening options (Gammon et al., 
2018).  
Rothwell et al. performed a modified patient preference study for the use of group genetic 
counseling for personal or family history of breast and/or ovarian cancer on cancer risk and BRCA1 
and BRCA2 testing (Rothwell et al., 2012). This study had 32 patients who underwent individual 
sessions and 17 who underwent group sessions (ranging from three to five patients in each group) 
and determined that both groups reported high satisfaction (Rothwell et al., 2012).  
While there are many benefits and positive outcomes to these different service delivery 
models, many of them cannot or have not been adapted to a pediatric setting. This is due to the 
unique nature of each patient’s indication and often the need for a physical assessment by a 
dysmorphologist or medical geneticist.  
2.2.5.4 Utilization of Genetic Counseling Assistants 
A more recent intervention to improve access to genetic counseling is the incorporation of 
genetic counseling assistants (GCA). While there is no formal scope of responsibility for GCAs, 
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common duties include clerical and administrative tasks, such as data entry, ordering supplies, and 
administrative work, that traditionally, GCs performed, thereby allowing more time for GCs to 
perform job duties specific to their specialized training (Pirzadeh-Miller et al., 2017). Pirzadeh-
Miller et al. performed a study at University of Texas Southwestern Medical Center (UTSW) that 
surveyed GCs, GCAs, and genetic counseling training program directors on experiences with 
GCAs and the scope of responsibilities for GCAs (Pirzadeh-Miller et al., 2017). The 22 GCs who 
responded to the survey stated that GCAs enabled them to have increased efficiency and time 
utilization (Pirzadeh-Miller et al., 2017). This study determined that GCs, GCAs, and program 
directors agree on the GCA responsibilities of administrative and clerical duties, however, there 
are conflicting responses on whether or not GCAs should call out negative or uncertain genetic 
testing results (all agree against calling out positive results) (Pirzadeh-Miller et al., 2017). 
Additionally, the study reported on their institutional patient volume as associated with the 
employment of GCAs. This study found that at UTSW, having a GC to GCA ratio of 3:1 yielded 
a 58.5% increase in new patients compared to no GCAs employed (Pirzadeh-Miller et al., 2017). 
2.2.5.5 Other Service Delivery Models 
GCs have developed other service delivery models to better utilize their time and improve 
patient outcomes by working independently, with non-genetics providers, or with different referral 
modalities. Kubendran et al. combined telegenetic counseling with triaging a medical genetics 
evaluation (Kubendran et al., 2017). Patients either had an in-person appointment with a 
pediatrician and a GC, an in-person appointment with the GC with a telemedicine medical 
geneticist, or an in-person appointment with only the GC. The pediatricians received training on 
genetic testing and evaluation of patients and saw patients who had nonsyndromic indications of 
birth defects, developmental delay, and autism, as well as evaluation for Marfan Syndrome and 
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Neurofibromatosis. Tele-geneticists were used in evaluation of syndromic indications, complex 
medical history, positive genetic tests with medical management, or negative genetic tests that 
warrant further investigation. Genetic counseling only was utilized for positive genetic test results 
that did not require a medical geneticist in ongoing management. Of the 265 patients, 149 were 
triaged to be evaluated first by the geneticist and 116 were triaged to the pediatrician, with 82 of 
those subsequently triaged onto the geneticist. 30 of the patients evaluated by the pediatrician and 
GC completed a survey and reported agreeing or strongly agreeing with all aspects of the genetic 
evaluation performed by the pediatrician, except for receiving information prior to the appointment 
regarding the nature of the visit. 71 of the patients evaluated by the geneticist via telegenetics 
completed a survey and 65% of the respondents preferred the telegenetics appointment instead of 
having to travel to the clinic (Kubendran et al., 2017).  
Hannig et al. developed a general genetic counseling clinic under the supervision of a 
medical geneticist to provide genetic counseling to patients who did not require a clinical exam or 
have complex medical management (Hannig et al., 2014). Over two years, 321 new patients were 
seen for indications including family history of a genetic syndrome, personal or family history of 
cancer, abnormal test results, known diagnosis, and other indications or concerns. By triaging the 
need for a medical geneticist, the clinic reduced the patient load for the medical geneticist by 291 
visits over the two years and allowed for patients to be seen in a timelier manner. Based on a survey 
of 30 patients seen by the GC only clinic, 77% of patients were satisfied or very satisfied with the 
wait time and 90% of patients were satisfied or very satisfied with aspects of knowledge of the GC 
and care they received (Hannig et al., 2014). Upon licensure and ability to bill for GC services, 
Heald et al. studied GC time involvement in GC only appointments compared to GC and MD 
appointments for cancer genetic counseling (Heald et al., 2013). Over eight months, six GCs saw 
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242 patients in the GC only appointments and 109 in the GC/MD appointments (Heald et al., 
2013). The time involvement for the GC was significantly less in the GC only appointments 
compared to the GC/MD appointments in case preparation (16.2 vs 29.8 minutes), appointment 
(52.3 vs 77.0 minutes), and follow up (27.0 vs 40.3 minutes), while still performing the same 
amount of activities per case, indicating GC only appointments, when possible, were a better use 
of a GC’s time (Heald et al., 2013). Similarly, CHP developed the GTC to provide genetic 
counseling appointments for non-genetics providers wanting to pursue genetic testing. This clinic 
also serves as a triage to the Medical Genetics department, for individuals with certain referrals 
and genetic test results that would benefit from the involvement of a medical geneticist. This novel 
service delivery model is the focus of this research.  
The Consent and Disclosure Recommendations (CADRe) Workgroup of the Clinical 
Genome Resource developed rubrics on consent for genetic testing and results disclosure for nine 
genes based on expert consensus (Ormond et al., 2018). The rubric delineates whether there should 
be traditional genetic counseling, targeted discussion, or brief communication based on the 
indication and test results. While not yet formally studied, the goal of this intervention is to best 
utilize GCs, to educate non-genetics providers in genetic testing, and create a collaboration 
between the two, while still providing quality patient outcomes (Ormond et al., 2018).  
Finally, there are other cases where GCs may not be utilized at all. This could be due to 
barriers to genetic counseling, non-genetics providers being comfortable with genetic testing either 
through additional training or experience, or other interventions that have been developed to 
provide appropriate genetic patient care. There are many educational aids developed by genetic 
testing laboratories, task forces, and medical centers that explain the genetic testing process to 
providers and patients. For example, Baylor College of Medicine developed Consultagene, an 
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online platform that provides educational materials, telegenetic counseling, peer-to-peer 
consultation, and interpretation of genetic testing results (Consultagene, n.d.). Another company, 
MyGeneCounsel, offers a subscription-based service for hospitals and patients to have up-to-date 
information and resources for a patient’s genetic test results (My Gene Counsel, n.d.). 
Additionally, Geisinger Health System developed a chatbot called Genetic Information Assistant 
(GIA) to follow-up with participants who had American College Of Medical Genetics and 
Genomics (ACMG) medically actionable results from research studies (Schmidlen, 2018). GIA 
provides information to participants about genetics, their results, how to follow up with a provider, 
and how to share this with their family one month after results were disclosed by a research 
assistant. So far, it has been piloted by 12 participants who said it was easy and intuitive to use, 
but they had mixed feelings about the genetic information being delivered by the chatbot 
(Schmidlen, 2018). 
2.3 Genetic Testing 
Genetic testing can be a complicated process, with complexities in the types of testing 
available, interpretation of results, nuances of genotype and phenotype correlation, psychosocial 
considerations, management of a patient based on results, and lab and test selection. Currently, 
about 75,000 different genetic tests are available, each with their own nuances (Concert Genetics, 
2018). The ordering provider must consider limitations of the technology, sensitivity and 
specificity of the test, the patient’s insurance coverage, and the lab expertise. Each of these factors 
must be considered to offer the patient the most appropriate genetic test (if any), and how to 
determine appropriate follow-up based on the results of the testing.  
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2.3.1 Genetic Test Selection 
A provider may order clinical genetic testing for a variety of reasons. Testing may be 
diagnostic or screening, depending on which test is used. Additionally, genetic testing can be used 
to determine etiology of the condition, understand how the natural history of the condition may 
affect the patient, assist with management and treatment, and for a patient’s own understanding. 
The affected person can be an adult, child, or even fetus. Testing can also be performed on 
unaffected individuals. This may be done for reproductive planning (carrier testing), cascade 
testing for cancer predisposition syndromes, pre-symptomatic testing for adult onset conditions, 
and parental testing to assist in interpretation of a child’s test result.  
Genetic testing can be carried out via several different methodologies depending on the 
type of variant suspected. An overview of germline genetic testing methodology is outlined in 
Table 1.  
 
Table 1. Overview of germline genetic testing methodology  
Methodology Identifiable variant Genome 
analyzed 
Benefits* Limitations* 
Sanger 
sequencing 
• Single nucleotide 
variants 
• Single gene 
• Panel 
• Accurate • Expensive 
Next generation 
sequencing (NGS) 
• Single nucleotide 
variants 
• Copy number 
variants 
• Single gene 
• Panel 
• Exome 
• Genome 
• Affordable • Needs to be 
confirmed by 
Sanger 
• Promotors and 
introns may not 
be fully assessed 
• CNV detection is 
not as reliable,  
Multiplex 
ligation-
dependent probe 
amplification 
• Copy number 
variants 
• Single gene 
• Panel 
• Can detect 
small deletions 
and 
duplications 
• Expensive 
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Fluorescence in 
situ hybridization 
(FISH) 
• Copy number 
variants 
• Translocations 
• Certain 
chromosomes 
or regions 
• Detect low 
level 
mosaicism 
• Can miss small 
deletions or 
duplications 
• Does not identify 
break points 
Karyotype • Large copy 
number variants 
or aneuploidy 
• Translocations 
• Genome • Affordable • Can miss small 
deletions or 
duplications 
• Cannot identify 
regions of 
homozygosity 
Array 
comparative 
genomic 
hybridization 
(aCGH) 
• Copy number 
variants 
• Panel 
• Genome 
• Broad test • Can miss small 
deletions or 
duplications 
• Cannot identify 
translocations 
Single nucleotide 
polymorphism 
array (SNP array) 
• Copy number 
variants 
• Regions of 
homozygosity 
• Panel 
• Genome 
• Broad test • Can miss small 
deletions or 
duplications 
• Cannot identify 
translocations 
• SNP coverage 
dependent 
Methylation 
analysis 
• Aberrations in 
imprinting 
• Certain regions 
of chromosome 
• Can diagnose 
methylation 
disorders 
• Cannot identify 
any other genetic 
change 
* Table only includes major benefits and limitations. Other benefits and limitations should also be considered in the 
context of the test methodology and the patient’s needs. 
Adapted from (Vento & Schmidt, 2012) 
 
Similarly, genetic testing can be performed on a variety of sample types, including blood, 
saliva, buccal, tumor, skin biopsy, amniotic fluid, and chorionic villus sampling. Each sample type 
may have associated benefits and limitations that must also be considered for each patient. For 
example, while blood is often the best sample for germline testing, if the individual had a bone 
marrow transplant, a skin biopsy sample would be best because their blood will contain both the 
patient’s DNA as well as the donor’s DNA. 
Once the genetic testing is agreed upon by both the patient and the ordering provider, there 
are many factors that need to be considered in proper lab and test selection. In A Guide to Genetic 
Table 1 Continued 
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Counseling, considerations for laboratory selection include genetic testing menu, specimen 
requirements, shipping information and kits, billing options, paperwork to accompany sample, and 
results (Uhlmann et al., 2009). In Practical Genetic Counseling for the Laboratory, other factors 
to consider in laboratory selection include financial considerations, technical factors, the ordering 
process, and customer service (McKinsey et al., 2017). In regards to financial considerations, the 
lab can bill the hospital, the patient’s insurance, or the patient directly, and factors such as hospital 
contracts and discounts, CPT® coding (Current Procedural Terminology) of the tests by the lab, 
the patient’s diagnosis(es) and corresponding ICD-10 (International Statistical Classification of 
Diseases and Related Health Problems) code(s), the patient’s insurance, cost of reflex or cascade 
testing, and if free testing is available to patients that meet certain criteria may influence the cost 
of the genetic test (Uhlmann et al., 2009). Providers should also consider technical factors of the 
test including the size of the panels, the assay used to call variants, and limitations with analysis 
of introns, regulatory elements, or binding sites. Furthermore, labs may differ on their 
classification of variants of uncertain significance (VUSs) and how changes in classification would 
be released. Providers may also consider whether they or their patients have access to raw data, 
research options, and if variant data is shared with public databases. For the ordering process, 
provider portals, notifications for insufficient or failed samples, and turnaround time must be 
considered. Customer service factors include quality of the lab report and availability of a lab GC. 
Additionally, labs should be certified by the Clinical Laboratory Improvement Amendments of 
1988 (CLIA), which are federal regulations for quality and safety in diagnostic testing in the United 
States and requires analytical validity, and accredited by the College of American Pathologists 
(CAP), which requires clinical validity and accuracy of diagnostic testing through a peer-based 
inspector model for U.S. and international labs ("Clinical laboratory improvement amendments 
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(42 usc 263a)," 1988; College of American Pathologists, n.d.). While this is not an exhaustive list, 
it contains many of the factors a provider should consider when ordering genetic testing for their 
patient to ensure it is the most appropriate test for the patient. CHP takes in account all of these 
factors in order to determine the laboratory/test formulary for genetic testing.  
Due to the nuances of identifying the most appropriate test and laboratory, understanding 
the complexities in genetics, and providing proper informed consent, ordering genetic testing can 
be cumbersome. However, genetic professionals, such as medical geneticists and GCs understand 
these complexities and are able to incorporate these factors to provide the best patient care.  
2.3.2 Genetic Test Results 
For most types of genetic testing, there are three potential results: positive, negative, and 
VUS. The ACMG and Association for Molecular Pathology (AMP) created guidelines for 
classification of genetic variants into five categories: benign, likely benign, VUS, likely 
pathogenic, and pathogenic, based on the current body of evidence (Richards et al., 2015). A 
pathogenic variant (formerly known as a mutation) is considered a positive result and a likely 
pathogenic variant is likely a positive variant; conversely, a benign or likely benign variant is 
considered a negative result (Richards et al., 2015). VUSs are complex as there is not enough 
information for the lab to determine if the variant is pathogenic or benign; however, as more data 
are collected the interpretation of any variant can be reclassified (Richards et al., 2015). The issue 
of variant classification is complicated by the fact that different labs can have different 
interpretations of the same variant. After the ACMG/AMP variant interpretation criteria were 
published, Amendola et al. reviewed the concordance of variant interpretation across nine 
molecular laboratories (Amendola et al., 2016). Ninety variants were reviewed by three 
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laboratories while nine variants were reviewed by all laboratories; there was an initial concordance 
of inter-laboratory variant classification of 34%, with 22% of differences affecting medical 
management, which then improved to 71% after consensus discussions, with five percent of 
differences affecting medical management (Amendola et al., 2016).  
2.3.2.1 Complexity of VUSs 
Due to the way genetic variants are interpreted, VUSs are more likely to be reported in 
genes that are not as well studied and in ethnic minorities (Caswell-Jin et al., 2018; Haffty et al., 
2009; Kessler et al., 2016; Martin et al., 2017). However, an estimated likelihood of receiving an 
uncertain result ranges from anecdotal reporting of one percent per gene analyzed to 7-52% in 
cancer panels (van Marcke et al., 2018). As more evidence is gathered, a VUS, or any other 
classification of variant, can be reclassified.  
The majority of literature on the reclassification of VUSs is in cancer genetics. In one 
cancer genetics clinic, five percent (40/1103) of genetic testing reports were updated over a three-
and-a-half-year time frame, but only 11% (30/266) of VUSs were reclassified; the majority of 
reclassifications were downgrading VUSs to likely benign (Macklin et al., 2018). Garrett et al. 
published about a website called FindMyVariant.org, a web-based educational resource for 
families with a VUS to aid reclassification through connection with other families and laboratories 
(Garrett et al., 2016). Tsai et al. found higher rates of VUS reclassification with increased familial 
testing (Tsai et al., 2018). Ninety-two patients who participated in FindMyVariant.org for over one 
year had an average of 4.5 relatives genotyped for the variant and yielded a VUS reclassification 
rate of 61% (38/62), the majority of which were downgraded to likely benign; the majority of these 
patients had VUSs in cancer genes (Tsai et al., 2018).  
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When a VUS result is received, current guidelines indicate to not use the variant to guide 
management, and instead to use the patient’s personal and family history to guide clinical decision 
making (Greenblatt, 2015; Richards et al., 2015). Furthermore, providers can aid in interpretation 
of the variant by pursuing family studies, research studies, documenting the phenotype for the 
laboratory and databases, and refer to a genetics center for further aid in interpretation (Greenblatt, 
2015). Additionally, there have been articles written for non-genetics providers to aid in their 
understanding of a patient’s VUS and what it means for management and interpretation (Lindor et 
al., 2013; Mahon, 2015; Sijmons et al., 2013).  
However, many non-genetics providers struggle with VUS interpretation (Eccles et al., 
2015; Macklin et al., 2019). A survey was sent to physicians at Mayo Clinic Florida with questions 
regarding demographic information, comfort of genetics and VUSs, and three knowledge 
questions on VUSs (Macklin et al., 2019). Of the 92 respondents, only 16% answered all 
knowledge questions correctly and 60% were not comfortable explaining a VUS result to their 
patient (Macklin et al., 2019). A similar study was performed with a survey sent to breast cancer 
specialists in the UK with questions regarding demographic information, genetics training and 
comfort, and two de-identified lab reports with VUS interpretations (Eccles et al., 2015). Only 
36% (56/155) of respondents were correct on VUS knowledge and skills questions; 84% of 
respondents correctly identified the first report as a VUS; however, the second report was correctly 
identified as a VUS in only 46% of the respondents and 23% interpreted the report as having no 
pathogenic variant (Eccles et al., 2015).  
Patient knowledge of VUSs is also poor, and studies have been performed for patient 
understanding of VUSs in chromosomal microarrays (CMA) (Kiedrowski et al., 2016; Reiff et al., 
2012) and cancer panels (Richter et al., 2013; Solomon et al., 2017; Vos et al., 2008). In Michigan, 
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a semi-structured phone interview was performed for 14 parents, whose child received a VUS 
result from a CMA 1-15 months after initial disclosure (Kiedrowski et al., 2016). Results were 
disclosed by a GC for nine of the patients and by a non-genetics provider from the neurology 
department for the remaining five patients. Although all parents could recount scientific 
uncertainty in the results, seven were confident the VUS was causal in the child’s medical 
concerns, and many contradicted themselves throughout the discussion; however, no distinction 
of who disclosed the results was mentioned in the analysis (Kiedrowski et al., 2016). A similar 
study was performed by Reiff et al. where semi-structured interviews were performed for parents 
of children with a CMA VUS (n=14) and a CMA pathogenic result (n=11) 1-24 months after initial 
disclosure (Reiff et al., 2012). Results were disclosed over the phone and/or in person by either a 
genetics provider (GC or geneticist) or a non-genetics provider with subsequent contact by a 
genetics provider. Five of the parents interpreted the VUS result as causal and ten parents reported 
difficulty understanding the results upon initial disclosure (Reiff et al., 2012). Finally, a 
questionnaire was mailed to patients who underwent cancer genetic testing at a Canadian facility, 
regardless of test result, to gauge test result comprehension, risk perception, cancer worry, and 
uptake of surveillance and/or risk reduction strategies (Richter et al., 2013). Of the 144 
respondents, those with VUS results had the highest observed rate of incorrectly recalled results 
(36%) compared to those with a pathogenic variant or no pathogenic variant identified (Richter et 
al., 2013).  
Research has shown patient’s and provider’s understanding of VUSs is lacking. However, 
GCs understand the uncertainty in pathogenicity and are skilled at explaining this complex concept 
to patients.  
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2.3.2.2 Genetic Nuances 
Even if genetic test results are clear, there are nuances of genomics that can complicate the 
interpretation. For example, variable expressivity and reduced penetrance can make test selection 
and interpretation of results more difficult, as genetic testing is not entirely predictive of the 
phenotypic outcomes for each patient. For example, a pathogenic variant in a cancer susceptibility 
gene often does not confer a 100% risk for cancer and a patient with a microdeletion might not 
have or develop all of the features found in other individuals with that microdeletion. Furthermore, 
there are technical limitations of certain testing. Besides methodological differences as mentioned 
previously, there can be lower coverage of certain genes or regions of genes, pseudogenes 
complicating testing of the desired gene, and mosaicism where platforms may vary on detection 
threshold. For example, even though a patient had whole exome sequencing completed, it is 
possible for the patient to have single nucleotide variant(s) in a gene that has a pseudogene, such 
as CYP21A2 and its pseudogene, CYP21A1, in Nonclassic Congenital Adrenal Hyperplasia. 
Genetic testing can only identify variants in regions of genes with sufficient coverage, and all 
genetic tests have certain variants they cannot identify.  
2.3.3 Psychosocial Considerations 
Certain ethical principles, such as autonomy, beneficence, and confidentiality, must be 
considered when offering genetic testing. Completion of genetic testing can yield unique ethical, 
legal and social implications (ELSI). As ELSI is a well-researched topic in genetic testing, several 
review articles have explored these issues (Broadstock et al., 2000; Ciarleglio et al., 2003; den 
Heijer et al., 2013; Evers-Kiebooms et al., 2000; Green et al., 2004; Heshka et al., 2008; Hirschberg 
et al., 2015; Sherman et al., 2010; Willis et al., 2017).  
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GCs are specially trained to work with these psychosocial considerations and help families 
address these issues. When GCs are involved prior to genetic testing, they are able to explore the 
possibility of psychosocial issues that may arise upon completion of genetic testing, ensure the 
patient is comfortable with the genetic testing ordered, and discuss any current psychosocial 
concerns related to the referral.  
2.3.3.1 Pediatrics 
The American Society of Human Genetics (ASHG) Board of Directors and ACMG Board 
of Directors issued a joint statement in 1995 regarding ELSI when performing genetic testing on 
minors and was updated in 2015 (American Society of Human Genetics Board of & American 
College of Medical Genetics Board of, 1995; Botkin et al., 2015). As children cannot consent for 
genetic testing, their guardians must act in the best interest of the child regarding pursuit of genetic 
testing. The initial report suggested genetic testing can be offered for children when there are 
timely medical benefits related to diagnosis, prognosis, and interventions and recommended 
deferral of genetic testing when there is absence of timely benefit and testing for adult onset 
conditions (American Society of Human Genetics Board of & American College of Medical 
Genetics Board of, 1995). The updated report still includes these recommendations and also 
elaborates on nuances specific to advances in genetic testing technologies (Botkin et al., 2015). 
While whole genome sequencing (WGS) technology is available, the report suggests pursuing 
genetic testing in a stepwise manner, from single gene or small panel, to larger panel, to targeted 
parts of the exome or genome as it relates to the patient’s phenotype; WGS is not recommended 
for healthy individuals (Botkin et al., 2015). Additionally, should secondary findings be elucidated, 
they should be actionable and disclosed to the family as decided during the informed consent or 
assent for adolescent (Botkin et al., 2015). The report also encourages providers and institutions 
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to follow other guidelines as they relate to microarray testing, newborn screening, and other 
genetic testing (Botkin et al., 2015).  
Unique psychosocial considerations of testing children that have been studied include: how 
the results will be disclosed to the parents and adolescent (McGowan et al., 2018) and revealing a 
parent’s carrier status after newborn screening (Ulph et al., 2015). McGowan et al. performed five 
focus groups to understand how adolescents and their parents want genetic testing results for 
secondary findings disclosed, and found preference for a collaborative decision-making approach 
of consent and assent that echoes the ASHG and ACMG report (McGowan et al., 2018). Relatedly, 
the results of the newborn screen and the implications for the parents can cause undue anxiety, 
distress, or parental guilt due to the way results are disclosed; while the anxiety and distress are 
often transient, greater support should be given when these results are disclosed (Ulph et al., 2015). 
GCs are trained on how to deliver difficult news and how to alleviate parental guilt in situations 
such as these.  
2.3.3.2 Impacts on Life and Relationships 
Once diagnosed with a genetic condition, or any chronic condition, one must adapt to that 
impact. One of the goals of genetic testing is to provide clarity to individuals and families on ways 
to improve their health or mitigate risk through behavior modifications. In a review of 30 studies, 
Heshka et al. found patients who tested positive for a condition that behavior change can benefit 
(such as increased cancer surveillance) had increased behavior modification and perceived their 
risk to be higher compared to patients who tested negative (Heshka et al., 2008). A different review 
of the literature identified that genetic disease severity does not predict adaptation, but can 
influence it; additionally, most individuals adapt well but there are those who do not, and children 
often parallel their parent’s adaptation (Biesecker & Erby, 2008). Providers can aid in active 
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coping through assisting patients to gain control over their genetic diagnosis or by encouraging 
ways for the patient to express their diagnosis (Biesecker & Erby, 2008). Additionally, providers 
can offer education and guidance on behavior modification to better patient compliance when there 
is a positive genetic diagnosis (Schneider & Schmidtke, 2014). Both of these tasks are routinely 
performed by GCs.  
Genetic testing not only has an impact on the individual, but also family members, partners, 
and friends. In focus groups consisting of both patients and healthcare providers, McAllister et al. 
sought to determine different effects the genetic diagnosis has on a family (McAllister et al., 2007). 
Of the seven focus groups, three had healthcare professionals, two had patient representatives, and 
two had patients. The patient group had two themes emerge: parent‐child communication 
difficulties and lack of diagnosis/inappropriate care (McAllister et al., 2007). The first theme refers 
to the challenge parents have with talking about the diagnosis to their children, while the second 
theme refers to the family burden in coordinating medical care for multiple individuals with a 
complex genetic diagnosis. While providers did not mention these negative outcomes, they instead 
focused on positive outcomes of a genetic diagnosis, such as heterozygote advantage and family 
fit (preference to have an affected child). These differences highlight the discrepancy between 
experienced family outcomes and provider’s perception of what those might be (McAllister et al., 
2007). However, GCs are aware of the possible psychosocial implications of a genetic diagnosis 
and are equipped with empathetic skills to help the family cope. In a similar study, Rivard et al. 
performed interviews of six fathers who have a child with a genetic diagnosis (Rivard & Mastel-
Smith, 2014). Using interpretive phenomenologic analysis, Rivard et al. identified themes 
including significant impact of diagnosis, seeking understanding, coping with the effect of the 
disorder, looking to the future, and addressing the father’s needs. Fathers often found themselves 
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as advocates for their child, educating themselves, and educating the medical providers about the 
condition. Additionally, the fathers did not report strain on their marital relationship, but did feel 
like they were left out of the education compared to their wives (Rivard & Mastel-Smith, 2014). 
Psychosocial outcomes were also assessed for siblings of individuals with a genetic diagnosis by 
Fanos et al. (Fanos & Johnson, 1995). Semi-structured interviews were performed for 54 cystic 
fibrosis siblings and yielded differing levels of risk perception to be a carrier by birth order, 
resentment if the sibling passed away young, and guilt if identified to be a carrier (Fanos & 
Johnson, 1995). A GC’s psychosocial training and counseling skills allow them to address the 
possible psychosocial outcome of genetic testing and how it could impact the family.  
Many studies also assessed the impact on family members in a cancer genetics setting. A 
prospective study on family relationships in individuals who had hereditary cancer predisposition 
genetic testing identified that 37% had positive family interactions, such as feeling closer, 
improved communication and support, and relief if testing was negative; however, negative family 
outcomes were identified in 37% of patients, including unwanted changes in relationships, 
problematic situations, conflicts, secrecy, communication problems, and feelings of guilt toward 
those who are carriers (van Oostrom et al., 2007b). Predictors of adverse consequences include 
reluctance to communicate about hereditary cancer and poor family functioning (van Oostrom et 
al., 2007b). The study expanded and explored how family relationships can aid or harm adaptation 
to genetic testing results (van Oostrom et al., 2007a). Individuals who report having inhibited 
conversations about hereditary cancer with relatives, poor family structure, or lack of support from 
a partner had more cancer related stress than those who did not (van Oostrom et al., 2007a). 
Therefore, open communication with their family and support from a partner can be key to 
reducing cancer related distress (van Oostrom et al., 2007a).  
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Genetic testing results can have impacts on patient’s and family’s lives, and GCs can help 
them explore support and encourage behavior modification and medical referrals.  
2.3.3.3 Other ELSI Considerations 
 The provider who orders genetic testing has certain ethical duties that must be performed. 
It is possible that genetic testing identifies non-paternity or that the patient’s parents are close 
blood relatives. It is recommended to include the possibility of identifying misattributed parentage 
during the pre-test process (C. F. Wright et al., 2019) and poses an ethical dilemma on to whom 
these results should be disclosed (Tozzo et al., 2014). Furthermore, pre-test counseling should 
include the possibility of identifying parental relationships (Rehder et al., 2013). ACMG released 
a report stating that both laboratories and clinicians need to have a policy in place when regions of 
homozygosity are indicative of a first or a second degree relationship between the parents, 
especially when the mother is young or has intellectually disability, as this can be indicative of 
rape (Rehder et al., 2013).  
Finally, upon a patient testing positive, there is a balance between the patient’s autonomy 
to choose to share the results with at risk relatives and the provider’s duty to warn at risk relatives. 
While court cases have yielded contradictory rulings on whether or not the provider has a duty to 
warn, institutions should have policies in place regarding expectations and regulations for 
disclosure of results to family members ("Pate v. Threlkel," 1994; "Safer v. Estate of Pack," 1996). 
Upon receiving consent to notify family members, a study identified a significant increase in 
proportion of family members receiving genetic testing (Suthers et al., 2006). Interventions, such 
as follow-up support upon positive testing (Gorrie et al., 2018) or direct communication with 
family members (Dheensa et al., 2018) may aid in dissemination of results to at risk family 
members. GCs assist patients once results are disclosed by writing a letter about the results and 
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making follow-up phone calls, both of which can increase patient understanding and familial 
cascade testing.  
GCs are acutely aware of these possibilities and are comfortable performing appropriate 
follow up with the patient.  
2.4 Utilization Management  
The Institute of Medicine Committee on Utilization Management defines UM as “a set of 
techniques used by or on behalf of purchasers of health care benefits to manage health care costs 
by influencing patient care decision-making through case-by-case assessments of the 
appropriateness of care prior to its provision” (Institute of Medicine (US) Committee on Utilization 
Management by Third Parties, 1989). More colloquially, UM may be referred to as the right test, 
at the right time, for the right patient. Therefore, UM practices are not based on cost savings, rather 
appropriate uses of medical decision making.  
Laboratory UM efforts started with routine testing, but genetic testing UM has come into 
light more recently. Both genetic testing laboratories and hospital systems are engaging in UM 
efforts by aiming to reduce errors in test selection, reduce repeat or redundant testing, increase cost 
savings, and improve patient impact. GCs in both clinical laboratories and hospital laboratories 
have a significant role in UM of genetic testing, as it both reduces medical costs while improving 
patient care (Kotzer et al., 2014). In addition to UM, Kotzer et al., in an opinion piece, argues that 
GCs in both lab and hospital settings can foster relationships with other clinicians in order to 
promote efficient genetic testing processes (Kotzer et al., 2014).  
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2.4.1 Laboratory Genetics Utilization Management 
Multiple genetic testing laboratories have utilized GCs and support staff to aid in UM of 
tests ordered, especially for duplicate or redundant testing, reflex testing, and tests with similar 
names (Anderson et al., 2012; Londre et al., 2017; C. E. Miller et al., 2014; Riegert-Johnson et al., 
2008; Wakefield et al., 2018). Anderson et al. reported on the role of the reference laboratory and 
laboratory GCs in regard to UM based on their experiences as GCs at Mayo Medical Laboratories 
(Anderson et al., 2012). They report three main domains in which they aid: review of 
appropriateness of similarly named tests, review the use of mutation screen vs known mutation 
test, and review for duplicate or redundant testing (Anderson et al., 2012).  
Duplicate genetic testing for HFE, TPMT, and CYP450 2D6 polymorphisms orders in 2006 
was analyzed at Mayo Medical Laboratories by Riegart-Johnson et al. (Riegert-Johnson et al., 
2008). The study identified 3.3% of TPMT, 0.9% of CYP2D6, and 0.3% of HFE orders were 
duplicates. While duplicate genetic testing is often not warranted, clinicians and laboratory 
personnel state that lack of time to review records, difficulty accessing genetic testing records, and 
lack of understanding that the duplicate testing will yield the same result, as reasons for duplicate 
testing (Riegert-Johnson et al., 2008).  
UM may be viewed from a cost savings perspective instead of appropriateness of tests. 
Miller et al. focused on the cost savings aspect of the UM efforts of the laboratory GCs and support 
staff at the reference laboratory, ARUP (C. E. Miller et al., 2014). Seven GCs at ARUP reviewed 
molecular orders as they were received and performed pre-analytical review of the test selection 
and clinical information provided based on predetermined criteria for clinical utility and cost-
effectiveness. If a discrepancy was identified, the GC reached out to the send out lab or ordering 
provider, explained the potential for improvement, and offered modification if desired. On 
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average, 99 genetic tests were modified each month, over 21 months. Of the modifications, 61% 
were misorders, such as sequencing, instead of mutation screen for carrier testing or targeted 
testing for a familial mutation, duplicate testing, or a test with a similar name; 34% were 
improvements; and five percent were other (C. E. Miller et al., 2014). The study was able to capture 
the benefits of UM modification as costs savings with an average savings to the payer of $792 per 
misordered test, but patient care was unable to be assessed (C. E. Miller et al., 2014). While patient 
outcomes were not overtly assessed, Miller et al. appropriately suggests these UM interventions 
benefit hospitals, labs, insurers, and patients (C. E. Miller et al., 2014).  
Another UM study of laboratory GCs was performed at Prevention Genetics (Londre et al., 
2017). Londre et al. reports on the UM interventions performed by GCs and other laboratory staff 
and performed modifications in 6.6% of tests ordered over the six-month period. These 
modifications include reflex testing, tiered testing, the use of NGS panels instead of Sanger 
platforms, cancelling duplicated tests, and identifying errors in test selection due to similarly 
named tests (Londre et al., 2017). These interventions allowed for a cost saving to the payers of 
$103,000 per month, with the biggest savings due to reflex testing and NGS testing (Londre et al., 
2017).  
Finally, a fourth laboratory, Molecular Genetics Laboratory at Cincinnati Children’s 
Hospital Medical Center, reported on the use of UM for genetic testing (Wakefield et al., 2018). 
GCs reviewed the molecular test orders after accessioning to review appropriateness of the test(s) 
selected, while duplicate test review was performed by a different department and not included in 
this analysis (Wakefield et al., 2018). Over six months, the GCs identified 109 flagged orders, 
which is 4.6% of all incoming orders (Wakefield et al., 2018). Similar to other studies, common 
order modifications included the use of a panel instead of individual genes, reflex or tiered testing, 
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redundant testing, targeted testing for known familial mutations, and inappropriate testing 
methodologies (Wakefield et al., 2018). The GCs offered 51 test modifications, of which 49 were 
changed, the two not changed were due to insurance prior authorization and New York State 
approval, averaging $2015.32 saved per modification, totaling to $98,750.64 saved (Wakefield et 
al., 2018).  
While these four genetic testing laboratories reported and assessed their UM interventions, 
many labs do have protocols to review proper test selection. Furthermore, it is suggested by these 
studies that by reaching out and educating providers, future order mistakes are prevented and a 
relationship with the GC is established as a resource for ordering questions (Kotzer et al., 2014; 
Londre et al., 2017; Wakefield et al., 2018).  
2.4.2 Hospital Genetics Utilization Management  
In addition to UM efforts on the laboratory side, hospitals employ UM efforts for genetic 
testing via send out review, consultative services, and formulary review (Dickerson et al., 2014; 
Mathias et al., 2016; Riley et al., 2015; Suarez et al., 2017).  
At Seattle Children’s Hospital, Dickerson et al. enacted a review of send-out testing 
meeting certain criteria: testing that costs more than $1000, order of multiple genetic tests, sending 
to a non-preferred or international lab, and sending out tests that can be performed in-house 
(Dickerson et al., 2014). These test orders were reviewed by two pathologists, a clinical chemist, 
and a GC, on a rotating basis. Of the 251 cases reviewed over the eight month study period, 24% 
were modified upon discussion with the ordering physician, with either sequential testing (11%) 
or cancellation (13%), while the other 76% were approved (Dickerson et al., 2014). Through this 
review, $118,952 was saved, or $463 was saved per test reviewed (Dickerson et al., 2014). When 
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accounting for the salary of the test reviewers, the hospital net saved approximately $55,000 over 
the eight months, making the UM review justifiable. The study also noted that 55% of genetic tests 
were ordered by non-genetics providers and that review of these orders often required an email or 
a phone call, while orders by genetics providers were often able to be reviewed with chart review 
alone (Dickerson et al., 2014).  
The UM program at Seattle Children’s was again studied by Mathias et al. after 30 months 
and 1,393 orders reviewed (Mathias et al., 2016). The one criterion that was modified after 27 
months for UM review was a price cutoff of $700. The UM review approved 67% of tests ordered, 
while 15% were changed to sequential testing, 10% were modified, and nine percent were 
cancelled (Mathias et al., 2016). Orders were often modified if there was an alternative test that 
offered improvement or better cost, while cancellation was often due to no preauthorization, 
deferral of testing, or wrong test selected (Mathias et al., 2016). The same proportion of tests 
ordered by non-genetics vs genetics providers and inpatient vs outpatient orders were approved 
upon UM review, but UM review yielded more cancellations for tests ordered by non-genetics 
providers, had more sequential tests for genetics providers, and modified more inpatient orders 
(Mathias et al., 2016). Additionally, of the 42 testing errors identified, the authors suggest 11 of 
these could have caused the diagnosis to be missed or unable to rule out the differential diagnosis. 
This study could only review one third of genetic test orders, due to the criteria, but notes that UM 
review is beneficial for cost savings and patients outcomes, even for genetic testing ordered by 
genetics providers (Mathias et al., 2016).  
In addition to review of genetic test orders, Riley et al. at Cleveland Clinic enacted a two-
part system of Clinical Decision Support Tools (CDST) and GC UM review to aid in utilization 
management of genetic testing orders (Riley et al., 2015). The CDST is a sort of formulary review 
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for 273 genetic tests that represent the highest cost to the institution. For inpatient orders, a clinical 
geneticist consult was required for testing that could not be deferred to the outpatient setting, and 
for outpatient orders, only certain providers were deemed authorized to order these tests. Riley et 
al. notes that this intervention actually yielded loss of potential revenue through insurance 
reimbursement (Riley et al., 2015). This intervention led to a genetics referral for 31% of outpatient 
instances and 25% of inpatient instances, while 48% of outpatient and 75% of inpatient instances 
did not further pursue genetic testing (Riley et al., 2015). The second intervention was GC UM 
review of all genetic testing ordered, including testing ordered by those authorized to do so. Over 
28 months of review, 261 tests were modified, yielding a total of $820,887 cost avoidance, or 
$29,317 avoided per month. Of the tests modified, 58% were cancelled, 18% were changed to 
reflex testing, and 24% were modified in other ways (Riley et al., 2015). Upon review of the 
success of the interventions, Riley et al. suggests certain genetic tests be allowed to be ordered by 
genetic professionals only, similar to some drugs needing to be prescribed by certain sub-
specialties (Riley et al., 2015).  
Finally, another genetic testing UM intervention was enacted at Stanford University 
Medical Center and analyzed by Suarez et al. (Suarez et al., 2017). The UM intervention was 
similar to Seattle Children’s, with review of send out genetic testing meeting certain criteria 
performed by a GC, a pathologist, and a geneticist. The criteria were: tests costing more than $2500 
(eventually lowered to $1800), concurrent genetic test orders, and sending to an international 
laboratory. Of the 629 genetic test orders reviewed over twelve months, 13% were classified as 
misorders (Suarez et al., 2017). Of the misorders, 42% were controversial orders, 29% had better 
alternative testing options, 17% were clerical errors, 10% were redundant testing and two percent 
were uncategorized misorders. An additional intervention was the availability of genetic testing 
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consultations provided by a GC, supported by two medical directors, at the start of the UM review 
intervention. The consultation included a review of the patient’s medical record, evaluation of 
testing options, and a recommendation for a genetic test. The consultation service was utilized 71 
times over the 12-month period. Additionally, misorders down trended and test modifications 
increased over the year, causing misordered genetic testing completed to decrease from 22% to 
3% (Suarez et al., 2017). Therefore, not only did these UM interventions allow for order correction, 
but also impacted future order decision making through proactive consultation services, with the 
goal to further reduce genetic test misorders (Suarez et al., 2017).  
2.5 Non-Genetics Provider’s Perceptions of Genetics 
While genetic testing is being ordered by non-genetics providers, research has shown that 
they are not as comfortable with genetics or genetic testing, and likely are not up to date with 
genetics knowledge, do not know how to interpret or follow-up based on results, and do not have 
sufficient time to go through all of the psychosocial considerations of genetic testing (Armstrong 
et al., 2015; Baars et al., 2005; Bensend et al., 2014; Diamonstein et al., 2018; Greendale & Pyeritz, 
2001; Guttmacher et al., 2007; Harvey et al., 2007; Hofman et al., 1993; Klitzman et al., 2013; 
McGovern et al., 2003; Salm et al., 2014; Thurston et al., 2007).  
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2.5.1 Knowledge, Awareness, and Attitudes of Genetics, Genetic Counselors, and Genetic 
Testing by Non-Genetics Providers  
Genetics can be applicable and relevant to all medical practices and patients; however, 
comfort, knowledge and utilization of genetics services may not be adequate in non-genetics 
providers. Diamonstein et al. performed a survey of non-genetics providers in Texas to assess these 
variables (Diamonstein et al., 2018). Of the 157 responses for practicing Texas physicians, 92% 
of Ob/Gyns reported genetics as moderately or very important to patient care, while 73% of 
pediatricians, and 24% of family and internal medicine providers felt the same, but most providers 
report discussing genetics more in their day-to-day practice in the past 5-10 years. Similarly, 
Ob/Gyns and providers in urban areas reported higher awareness of genetic services, such as 
referring for GC services and genetic testing. However, 72% of respondents report rarely or never 
referring to genetic counseling services, but are more likely to refer if they report importance to 
patient care. The study also surveyed perceived barriers to genetic counseling services and 
identified preferential referral to a geneticist instead, genetic counseling is not indicated, lack of 
knowing GCs to refer to, lack of knowing when a GC referral is appropriate, and not knowing how 
to refer to a GC (Diamonstein et al., 2018). These barriers to genetic counseling can be overcome 
with education resources that provide an overview of genetics and awareness of the availability of 
GCs.  
A study performed in the Netherlands by Baars et al. identified similar results in that 
pediatricians and Ob/Gyns had greater genetics knowledge than general practitioners (Baars et al., 
2005). A genetics knowledge survey was sent to 200 general practitioners, 300 Ob/Gyns, and 265 
pediatricians in the Netherlands to build upon a previous genetics knowledge survey done by 
Hofman et al. in the United States in 1993 (Hofman et al., 1993). Regardless of specialty, Baars 
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reports that more recent graduation from medical school, genetics electives, and practicing in an 
urban center correlate with higher knowledge scores, emphasizing the need for continuing genetics 
education for practicing physicians, especially general practitioners and those in rural areas (Baars 
et al., 2005).  
Klitzman et al. surveyed 220 internists (response rate 19.9%) at two academic medical 
centers to identify attitudes and practices regarding genetic testing (Klitzman et al., 2013). The 
survey identified that the majority (87.1%) of respondents rated their knowledge of genetic testing 
as somewhat or very poor, yet many (39.7%) still ordered genetic testing for their patients. 
Additionally, internists were more likely to order genetic testing if the patient asked about it and 
if patient is not African American, raising concerns about utilization of genetic testing and access 
to it. Despite these alarming numbers, the respondents did mention the need for further genetics 
training (Klitzman et al., 2013).  
2.5.2 Genetics Education in Medical School 
In order for primary care physicians (PCPs) and other non-genetics physicians to provide 
basic genetic testing and interpretation of results, there needs to be a foundation of genetics training 
in medical schools. The Association of Medical Colleges issued a report on genetics education in 
2004, which stated competencies for education of the general physician in prevention, diagnosis, 
and treatment of genetic conditions, outlined concepts of attitude, knowledge, and skills related to 
genetics, and listed educational strategies to attain these goals (Korf, 2004). Some concepts 
included in the report are the need for physicians to recognize the role of genetics in health, 
treatment, and prevention, and the psychosocial consideration regarding genetic information, 
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recognizing when to refer a patient for genetic counseling, and explain and obtain informed 
consent (Korf, 2004).  
A survey of U.S. and Canadian medical genetics course directors and curricular deans was 
performed by Thurston et al. in order to elucidate the genetics education in medical school 
(Thurston et al., 2007). Of the 75.2% of medical schools that responded, the majority (62%) report 
between 20 and 40 hours of genetic didactics, primarily in the first two years of medical school. 
Genetics instruction was described as “a broad survey of medical genetics concepts” with more 
than 90% of respondents including coursework on cancer genetics, mendelian genetics, and 
multifactorial inheritance; however, emerging genetics topics such as immunogenetics were taught 
in less than 50% of responding schools and few schools (11%) incorporated practical application 
of genetics knowledge. Thurston et al. reports that most schools teach on interpretation of genetic 
results and delivery of results, but was not able to assess teaching on informed consent and 
evaluation of genomic literature (Thurston et al., 2007).  
Suggestions on improving medical school genetics training and continuing education of 
physicians was proposed in an opinion piece by Guttmacher in 2007 (Guttmacher et al., 2007). 
Guttmacher proposes that PCPs need to correctly identify patients who need further investigation 
or referrals to specialists, including geneticists, understand frontline genetic testing and results 
interpretation, and incorporate informed consent. In order to educate providers on these topics, 
Guttmacher suggests thorough education in medical school, including incorporation of patient care 
rather than lectures on broad concepts, and continuing education for providers with access to 
common genetics resources online (Guttmacher et al., 2007).  
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2.5.3 Benefits and Limitations to Genetic Testing Ordered by Non-Genetics Providers 
While doctors order genetic tests in an effort to aid in the care of their patients, there can 
be unintended negative consequences when a non-genetics provider orders genetic testing. 
Bensend et al. performed a study to elucidate GCs’ negative experiences when non-genetics 
providers order genetic testing, as such it is a biased study that sought problems with non-genetics 
providers ordering genetic testing (Bensend et al., 2014). They performed phone interviews with 
15 GCs in Minnesota who were aware of a negative outcome from genetic testing ordered by non-
genetics providers. Of the 37 specific incidents that occurred in Minnesota, 20 were related to 
cancer genetics, four were related to general genetics, four were related to prenatal genetics, and 
nine were in other specialties; 10 of these involved primary care physicians, four Ob/Gyns, three 
oncologists, and 14 providers from other specialties. They used inductive and case analysis 
methods and identified six domains: “psychosocial/emotional effects, inadequate genetic 
counseling, errors related to genetic tests and screening, medical mismanagement, negative 
attitude toward medical provider(s), and unnecessary use of health care resources” (Bensend et al., 
2014). Regarding errors related to genetic tests and screening, all 13 cases had inaccurate 
information about interpretation of results, four had inappropriate genetic testing performed, four 
had incorrect genetic testing performed, and three had incomplete genetic testing (Bensend et al., 
2014). Based on these descriptions of the themes and specific examples, utilization of GCs would 
have likely prevented these situations from occurring.  
Greendale et al. discusses the benefits and limitations of utilizing PCPs for genetic services 
(Greendale & Pyeritz, 2001). PCPs tend to have a longitudinal relationship with their patients and 
this relationship can be beneficial when something as sensitive as genetic testing is ordered. One 
potential use of PCPs is to order genetic testing for straightforward indications. If the test is 
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positive, then the patient would need to be referred for proper follow up and care, but if the test is 
negative, the PCP would need to assess if the patient would still benefit from a thorough genetics 
evaluation. Additionally, the burden of knowing when to refer to medical genetics is imperative 
from a legal, mal-practice perspective (Greendale & Pyeritz, 2001). While this model could be 
beneficial, the risk of missing a referral and the fact that the model does not include comprehensive 
pre-test genetic counseling is a significant drawback.  
Once a genetic test is ordered by a non-genetics provider, the report should be 
understandable by medical professionals other than geneticists and GCs. However, McGovern et 
al. performed a survey of NSGC members and identified that the majority of GCs have had to 
contact the laboratory to “obtain clarification of a report interpretation (83%), information about 
the methodology used (82%), interpretation of results (81%), and revised risks after negative test 
results (69%)” (McGovern et al., 2003). Furthermore, 28% of survey respondents indicated that 
genetic testing reports frequently needed to be clarified prior to disclosure to the patient. 
McGovern argues that if that many GCs require clarification, then PCPs and other non-genetics 
providers would require even more contact and clarification with the lab, or else misinterpret the 
genetic testing results (McGovern et al., 2003). 
At CHP, the GTC was created to marry the benefits of non-genetics provider’s ordering of 
genetic testing with the availability of GCs to ensure proper pre-test counseling and post-test 
follow up. Through this service delivery model, non-genetics providers are able to assess all their 
patients to see if the patient would benefit from genetic testing, without having to sacrifice clinic 
time to review the testing process. Additionally, the UM review of the GCs creates a “safety nest” 
ensuring the best test for the patient is selected, without requiring the non-genetics provider to be 
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up to date on the latest genetics knowledge. The GTC is a novel service delivery model, and its 
unique benefits and limitations have not yet been assessed.  
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3.0  Manuscript 
3.1 Background 
Genetic testing accounts for a significant portion of healthcare spending in the United 
States (UnitedHealth Center for Health Reform and Modernization, 2012) and there are 
approximately 75,000 different genetic tests available on the market today (Concert Genetics, 
2018). Therefore, choosing the most appropriate test for each patient is imperative, as results can 
be informative for treatment, management, and understanding of recurrence risk (Uhlmann et al., 
2009). Many hospital institutions and genetic testing laboratories have implemented utilization 
management (UM) programs in order to aid proper selection of genetic testing (Anderson et al., 
2012; Dickerson et al., 2014; Kotzer et al., 2014; Londre et al., 2017; Mathias et al., 2016; C. E. 
Miller et al., 2014; Riegert-Johnson et al., 2008; Riley et al., 2015; Suarez et al., 2017; Wakefield 
et al., 2018). These studies identified that UM efforts improve patient care by reducing redundant 
or duplicate tests, ensuring appropriateness of test, and often yield cost savings. Genetic testing 
UM is often supported by the work of genetic counselors (GCs).  
GCs are master’s educated medical professionals who discuss the role of genetics in an 
individual’s or family’s medical concerns, inform the patient of the intricacies of genetic testing, 
and provide psychosocial support (Resta et al., 2006). GCs render their services in a variety of 
healthcare settings, including pediatrics, cancer, prenatal, neurogenetics, and more (National 
Society of Genetic Counselors, n.d.). Benefits to genetic counseling include better patient recall 
knowledge and more appropriate genetic testing compared to patients who have genetic testing 
ordered by a non-genetics provider (Cragun et al., 2015). This is due to non-genetics providers not 
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being comfortable with genetics, not having up to date knowledge on genetics, and not having 
enough time to review all the medical and psychosocial implications of genetic testing (Armstrong 
et al., 2015; Baars et al., 2005; Bensend et al., 2014; Diamonstein et al., 2018; Greendale & Pyeritz, 
2001; Guttmacher et al., 2007; Harvey et al., 2007; Hofman et al., 1993; Klitzman et al., 2013; 
McGovern et al., 2003; Salm et al., 2014; Thurston et al., 2007). However, there is a workforce 
shortage of GCs and medical geneticists (Hoskovec et al., 2018). While GCs and Medical 
Geneticists understand the nuances of genetic testing, non-genetics providers, who are often not 
as well versed in these details, are ordering more genetic testing as wait times for genetics 
appointment increase and genetic testing becomes more common (Klitzman et al., 2013).  
In order to address the workforce shortage and diversifying needs of the patient 
communities, different service delivery models, such as telegenetics, group genetic counseling, 
and other unique service delivery models, have been implemented with success on providing 
greater access to valuable GC services (Buchanan et al., 2015; Buchanan et al., 2016; Calzone et 
al., 2005; Cohen et al., 2013; Gammon et al., 2018; Hannig et al., 2014; Heald et al., 2013; Hilgart 
et al., 2012; Kubendran et al., 2017; Ormond et al., 2018; Otten et al., 2016; Rothwell et al., 2012; 
Schmidlen, 2018). UPMC Children’s Hospital of Pittsburgh (CHP) created an innovative genetic 
counseling service delivery model: the Genetic Testing Clinic (GTC).  
The GTC is a genetic counseling-only clinic that offers same-day and advance-scheduled 
appointments for referrals from non-genetic providers within CHP ordering a genetic test. This 
clinic is unique in that it incorporates utilization management (UM) for the requested genetic test 
while providing comprehensive pre-test genetic counseling. In order to evaluate the benefits, 
possible limitations, and role of the GTC, the study assessed the benefits and genetic testing 
outcomes of this novel service delivery model one year after its inception and assessed outcomes 
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of genetic testing ordered by non-genetics providers prior to the creation of the GTC. The purpose 
of this study was to assess pre-test and post-test outcomes of genetic testing completed by non-
genetics providers prior to the inception of the GTC compared to genetic testing completed through 
the GTC. Additionally, the study aimed to explain any differences in outcomes that are found. 
Finally, the study wanted to capture how genetic testing trends at CHP changed over the years.  
3.2 Methods 
This study was approved under Expedited Review, with a waiver of informed consent and 
HIPAA authorization, by the University of Pittsburgh Institutional Review Board (IRB) 
(PRO18060616) (Appendix A).  
3.2.1 Study Population 
UPMC Children’s Hospital of Pittsburgh (CHP) is a nationally recognized, academic, 313 
bed children’s hospital in urban Western Pennsylvania.  
Patients who completed genetic testing on an outpatient basis at CHP in 2017 and 2018 
were included in the study. The study consists of two groups: patients who had genetic testing 
ordered and completed by non-genetics providers in 2017 and patients who had genetic testing 
ordered and completed through the Genetic Testing Clinic (GTC) in 2018. The first 150 patients 
who had genetic testing completed by non-genetics providers in 2017 were included in the study 
and GTC patients from 2018 were included until 150 had completed genetic testing. Thus, GTC 
patients who deferred genetic testing upon pre-test counseling, whose genetic testing was denied 
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by insurance, who did not get their sample drawn or whose insurance authorization expired, or 
were referred to medical genetics or neurogenetics were also assessed. Because insurance 
authorization can take time, some patients in the non-genetics group were seen in the year prior, 
yet genetic testing was drawn and completed in 2017. Additionally, non-genetics patients who 
were recommended genetic testing but did not complete it, due to lack of insurance approval or 
the patient not completing sample collection, were not included in the sample. For the purposes of 
this study, genetic testing is defined as germline molecular or cytogenetic testing for the purpose 
of diagnosis. As such, biochemical testing and tumor testing were excluded from the study. The 
exclusion criteria for the non-genetics providers group was the involvement of a GC or medical 
geneticist during the ordering process. At CHP, a GC is always involved in genetic testing in the 
Ophthalmology department and sometimes involved in the Neurology department. The GTC sees 
patients for pre-test counseling (with post-test counseling), post-test counseling only, and infants 
who had positive newborn screening tests (NBS) for cystic fibrosis (CF) but had negative follow-
up sweat testing. As this study aims to capture the outcomes of utilizing the GTC from the start of 
the genetic testing process, referrals for post-test counseling only and CF NBS were excluded.  
3.2.2 Data Identification 
Identification of patients was completed using two methods. For the non-genetics patients 
in 2017, a request was sent for data on genetic laboratory testing completed through CHP in 2017, 
as all genetic testing completed at CHP must be sent out through the hospital laboratory. The report 
provided by the analyst was edited to include relevant genetic tests by the Genetic Counseling 
Supervisor of Laboratory Services at CHP, before the study PI completed data collection. There is 
no method available to identify when genetic testing is recommended or ordered by non-genetics 
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providers at CHP, unless it is actually completed. This report was also pulled for 2018 to assess 
the extent of a genetics provider’s involvement in genetic testing.  
For the GTC patients in 2018, the GCs utilize a Microsoft Access Database that is provided 
through a collaborative partnership with the Patient-Centered Laboratory Utilization Guidance 
Service (PLUGS) group, based out of Seattle Children’s Hospital. A report was pulled for all the 
patients seen in the GTC, including post-test counseling only and CF NBS patients, which were 
filtered out.  
3.2.3 Data Collection 
The study PI used the two reports to identify patients for inclusion in the study using the 
inclusion and exclusion criteria and completed the retrospective electronic medical record chart 
review. Using the name on the report, the patient was looked up in the electronic medical record 
(Cerner®) at UPMC Children’s Hospital of Pittsburgh and the medical record number (MRN) was 
saved in a separate Excel spreadsheet, according to IRB protocol. The ordering provider’s 
corresponding note was identified, and demographic information, including age, race, sex, 
indication for testing, and insurance, at the time of visit was recorded by reviewing the patient 
information and visit history documented in the electronic medical record.  
For the non-genetics patients, the clinic note was read to determine if certain aspects of 
pre-test counseling were discussed and documented in the note. A definition for risks, benefits, 
limitations, types of results, incidental findings, family history, and letter of medical necessity 
(LMN) language were determined prior to review of records, and the clinic note was compared 
against these definitions and recorded. These definitions are provided below, in Table 2.  
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Table 2. Definitions of pre-test terms 
Term Definition 
Risk Documentation of emotional consequence of genetic testing, pain of the blood draw, 
GINA, the word “risk”, or other risks specific to the genetic test 
Benefit Documentation of the possibility of having a diagnosis to aid in management or 
reproductive plans for the family, the word “benefit”, or other benefits specific to 
the genetic test 
Limitation Documentation of the possibility that genetic testing does not yield a diagnosis, either 
due to current technology or knowledge or the specific gene was not tested, or if it 
does yield a diagnosis there may be variable expressivity or reduced penetrance 
causing difficulty in prediction of specific health implications, the word 
“limitation”, or other limitations specific to the genetic test 
Types of results  
Positive Documentation of a specific diagnosis the genetic testing can identify, the word 
“positive”, or other positive results specific to the genetic test. 
Negative Documentation of the patient not having a specific diagnosis the genetic testing can 
identify, the word “negative”, or other negative results specific to the genetic test.  
Variant of 
Uncertain 
Significance 
(VUS) 
Documentation of genetic testing yielding a result that is not currently understood by 
genetics, the word “variant of uncertain significance” or “VUS”, or other variant 
of uncertain significance results specific to the genetic test 
Incidental 
finding 
Documentation of genetic testing being able to identify aspects unrelated to the 
patient’s presenting phenotype, such as non-paternity or a different genetic 
condition, the word “incidental finding”, or other incidental findings specific to 
the genetic test 
Family History  
None No documentation of any family medical concerns 
Targeted Documentation of the presence or absence of the patient’s phenotype, or related 
symptoms, in family members, or documentation of family medical concerns 
specific to that provider’s specialty 
Full Documentation of the presence or absence of the patient’s phenotype, or related 
symptoms, in family members, and documentation of unrelated medical concerns 
in third degree relatives 
LMN language Documentation for justification for the genetic testing due to aiding medical 
management, cost savings, practice guidelines, of other aspects of justification 
specific to that patient and the genetic test. 
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Due to the protocol of pre-test counseling in the GTC, all key elements of pre-test 
counseling, including: discussion of risks, benefits, limitations, the possibility of incidental 
findings, the possible types of results, and eliciting a full family history, are discussed and 
documented. The GTC utilizes clinical note templates that reflect this standardized approach. As 
such, for the purposes of this study all GTC patients are recorded as receiving the most 
comprehensive pre-test counseling possible. 
Additionally, clinical utility of the genetic test and if the genetic test was most appropriate 
was assessed and recorded for non-genetics patients. The study PI documented the history of 
present illness (HPI), the genetic testing ordered, and if previous genetic testing was completed for 
each non-genetics patient. Two licensed and certified GCs in the GTC independently reviewed 
each HPI and the genetic test ordered and determined if the genetic test had clinical utility and if 
it was the most appropriate for that patient. If the two coders determined the same interpretation 
of clinical utility or if the genetic test was most appropriate, consistency was established. If 
responses differed, then the senior GC on the research project and Genetic Counseling Supervisor 
of Laboratory Services blindly reviewed the case and acted as a tie breaker.  
Finally, the testing for the non-genetics patients was assessed and recorded to see if it was 
the preferred laboratory/test based on the CHP genetic testing formulary. The Laboratory 
Utilization Management team at CHP maintains a time-stamped copy of the genetic testing 
formulary for CHP. The 2017 genetic testing formulary list was used to assess whether the correct 
laboratory/test was chosen for each non-genetics patient.  
Due to the GTC’s protocol to have the GC thoroughly review each genetic testing referral 
for clinical utility, appropriateness of the genetic testing, and proper selection of laboratory, all of 
the GTC patients are recorded as receiving testing that had clinical utility, was appropriate, and 
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performed at the institution’s preferred laboratory. Should the GC suggest any modifications of 
genetic test orders to the referring provider in order to reach clinical utility, appropriate genetic 
testing, or a use the institution preferred lab, documentation is performed in the EMR.  
For the GTC, the clinic note was read to determine and record if there were additional 
benefits by having a GC. This included if there was a referral based on unrelated family history 
and if the GC discussed alternative genetic testing options with the referring provider. The GTC 
may provide unrelated family history referrals or contact information for a service different than 
the patient’s presenting medical concerns. The GC may discuss alternative genetic testing options 
and the associated pros and cons of each test, based on discussion of the goals of genetic testing, 
family history assessment, and genetic testing formulary.  
Additionally, for the GTC, the Cerner® “phone messages” note type and clinic notes from 
the referring provider were reviewed to determine and record if the referring provider attempted 
to complete the same genetic testing for which the patient was referred to the GTC.  
Further chart review for both non-genetics and GTC patients included review of past 
laboratory testing and scanned documents to determine and record if previous genetic testing was 
completed. If previous genetic testing was completed, assessment was performed on the genetic 
test ordered to determine if there was redundant genetic testing ordered. For example, if a patient 
already had an epilepsy panel and then the provider ordered POLG sequencing, the POLG testing 
is redundant as POLG was already assessed on the panel. However, if a patient previously had 
POLG sequencing and then the provider ordered an epilepsy panel, the panel is not redundant, as 
there are other genes on the panel that were not previously assessed.  
In order to determine insurance outcomes of genetic testing ordered by non-genetics 
providers and the GTC, clinical notes and “phone messages” were reviewed to record date of 
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appointment, date of submission to insurance, and date of insurance decision, as documented in 
the phone messages. If the phone message included an initial denial by insurance that was then 
approved, the date of the denial and the subsequent approval were both recorded. If the phone 
message documented a provider doing peer-to-peer with the insurance company, it was recorded. 
If the phone message included documentation of insurance requesting LMN language or a smaller 
genetic test, this was also recorded. If a date of insurance outcome was unknown, is was recorded 
as such.  
For post-test outcomes, the laboratory results were reviewed to determine if the genetic 
testing was positive, negative, VUS, at least carrier (hereafter called carrier), or pharmacovariant, 
these definitions are provided in Table 3. The report was read to determine if the laboratory 
recommends parental testing and if it would be performed at no cost. If family testing was 
recommended, phone messages, clinic notes, and lab reports were reviewed to see if it was 
completed. If it was completed, review of the updated genetic testing report was completed to 
determine and record if parental testing reclassified a VUS. 
 
Table 3. Definitions of results 
Term Definition 
Positive  Pathogenic or likely pathogenic variant(s) that are in congruence with the 
inheritance pattern of the disease (ex: one single nucleotide variant identified in 
an autosomal dominant condition, or two single nucleotide variants identified in 
an autosomal recessive condition) 
Negative No pathogenic, likely pathogenic, or VUSs identified 
VUS Variant of Uncertain Significance identified in an autosomal dominant or autosomal 
recessive condition 
At least carrier 
(Carrier) 
Likely pathogenic or pathogenic variant in an autosomal recessive condition, no 
second variant identified or ruled out 
Pharmacovariant Single nucleotide variant that has implications for pharmaceutical dosing, but does 
not have disease manifestation  
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Finally, phone messages and clinic notes were read for the non-genetics and GTC patients 
to determine and record if there was a triage or referral to Medical Genetics (a clinic at CHP with 
a medical geneticist and GC) or Neurogenetics (a clinic at CHP with a medical geneticist, 
neurologist, and GC), which may aid in management and diagnosis of medically complex patients.  
3.2.4 Data Analysis 
Demographics, including age, sex, race, insurance type, and ordering department or referral 
department, were assessed using descriptive statistics by whether or not the genetic test was 
ordered through a non-genetics provider or through the GTC to understand characteristics of each 
sample. Types of tests ordered by non-genetics providers and referral departments to the GTC 
were analyzed with descriptive statistics and a two-tailed chi-square test was performed for types 
of tests ordered through non-genetics providers compared to the GTC to identify trends in test 
ordering. Exome tests were excluded from this analysis, as exomes can only be ordered through a 
genetics provider, based on CHP policy. Post-hoc analysis of the chi-square results was a test of 
proportion using two-tailed Fisher’s exact comparing the proportion of each test that was ordered 
by non-genetics providers compared the proportion the test was ordered by the GTC, with a 
Bonferroni corrected p-value of 0.007.  
Analysis of pre-test outcomes included a two-tailed unpaired t-test for comparison of 
length of time from appointment to insurance authorization submission and length of time from 
insurance authorization submission to approval between non-genetics and GTC patients who 
completed genetic testing to assess if there is a statistically significant difference in length of time 
between non-genetics providers and the GTC in obtaining insurance authorization. Two-tailed 
Fisher’s exact test was used to compare if LMN language was in the note or not and if insurance 
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requested LMN language between non-genetics providers and the GTC to assess if there is a 
statically significant difference in proportion of notes having LMN language and requests by 
insurance for LMN language between non-genetics providers and the GTC. An unpaired t-test with 
Welch’s correction for unequal variances was used to compare length of time for insurance 
authorization of non-genetics patients who had LMN language in the note compared to those that 
did not have LMN language. Additionally, descriptive statistics were used to asses if the patient 
had genetic testing previously for both the non-genetics patients and the GTC patients. 
Pre-test outcomes unique to non-genetics providers were assessed with descriptive 
statistics and was performed for non-genetics patients, including assessing: if the test had clinical 
utility for the patient, if the test was the most appropriate for the patient, and if the test was 
performed at an institution preferred laboratory to better understand the characteristics of genetic 
testing as ordered by non-genetics providers. A two-tailed chi square test was performed 
comparing if the genetic test selected was the most appropriate for the patient or not. Post-hoc 
analysis of the chi-square results was a test of proportion using two-tailed Fisher’s exact comparing 
the proportion of times each type of test selected was the most appropriate or not compared to the 
average rate of most appropriate test, with a Bonferroni corrected p-value of 0.01. Additionally, 
descriptive statistics were used to assess documentation by non-genetics providers and the GTC 
of risks, benefits, and limitations associated with genetic testing; the possible types of results; the 
extent of family history; and the possibility of incidental findings by the ordering department in 
order to assess documentation of informed consent and family history. Further analysis included 
two-tailed Fisher’s exact test to compare documentation of either zero or one risk, benefit, or 
limitation (it did not assess differences if two or three categories of risk, benefits, or limitations 
were documented) and documentation zero or one possible type of result (it did not assess 
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differences if two or three types of possible results were documented) between neurology and 
endocrinology; and two-tailed chi square test was performed for documentation of no, targeted, or 
full family history between neurology and endocrinology to better understand differences in 
informed consent and documentation of family history between non-genetics departments. 
Finally, pre-test outcomes unique to the GTC were assessed for all GTC patients with 
descriptive statistics for when the referring provider attempted insurance authorization before 
referral to the GTC, if a test modification was suggested, and when a referral was made by the 
GTC for unrelated family history to better understand the unique benefits of the GTC.  
Analysis of post-test outcomes included two-tailed chi-square test of positive, negative, or 
VUS results between non-genetics and GTC patients to assess if there were differences in genetic 
testing results between non-genetics patients and GTC patients. Additionally, descriptive statistics 
were used for type of result by department and type of result by test for both non-genetics patients 
and GTC patients to assess trends in test results. Finally, two-tailed chi-square test was also 
performed for whether a referral to medical genetics or neurogenetics was provided between non-
genetics providers and the GTC to assess if there is a difference in referral making patterns between 
the two service delivery models.  
Regression modeling was performed to understand the interaction between demographics, 
pre-test variables, and post-test variables. A multiple linear regression model was used to assess 
whether the patient’s age, sex, race, insurance type, if they have secondary insurance, if the test 
was ordered through non-genetics providers or the GTC, and what department was the 
ordering/referral department, are related to the length of time from the appointment to insurance 
authorization submission. Similarly, a different multiple linear regression model was used to assess 
whether the patient’s age, sex, race, insurance type, if they have secondary insurance, if the test 
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was ordered through non-genetics providers or the GTC, what department was the ordering/referral 
department, if the provider’s note included LMN language, and if insurance requested LMN 
language are related to the length of time from insurance authorization submission to insurance 
decision. A multinominal logistic regression model was used to assess whether the patient’s age, 
sex, or race, if the patient had previous genetic testing completed, the type of genetic test ordered, 
if the test was the most appropriate test for the patient, if the test was ordered through non-genetics 
providers or the GTC, and what department was the ordering/referral department are related to the 
genetic test result. Similarly, a different multinominal logistic regression model was used to assess 
whether the patient’s age, sex, or race, the type of genetic test ordered, if the test was ordered 
through non-genetics providers or the GTC, what department was the ordering/referral department, 
and the genetic test result are related to whether there is a medical genetics or neurogenetics 
referral.  
The majority of statistical tests were completed using GraphPad Prism (v. 8, San Diego, 
CA) with the exception of regression modeling, which was completed with Stata (v. 15, College 
Station, TX). Statistical significance for all analyses was based on the conventional alpha level of 
significance at p<0.05, unless otherwise noted.  
3.3 Results 
3.3.1 Patient Information 
Genetic testing was completed for patients of a variety of demographics (Table 4). Of the 
150 patients analyzed for the non-genetics group, the majority (90/150, 60%) were eight years of 
 61 
age or younger at the time of consultation for genetic testing; about half (71/150, 47.33%) were 
male; the majority (126/150, 84%) were white; about half (84/150, 56%) had commercial 
insurance as their primary or only insurance; and the majority had testing ordered through 
neurology (77/150, 51.33%) or endocrinology (40/150, 26.67%). Of the 150 patients who 
completed genetic testing through the GTC, the majority (83/150, 55.33%) were eight years of age 
or younger at the time of consultation for genetic testing; about two-thirds were male (53/150, 
64.67%); the majority (138/150, 92%) were white; about half (86/150, 57.33%) had commercial 
insurance as their primary or only insurance; and the majority were referred by neurology (83/150, 
55.33%).  
 
Table 4. Demographics 
Demographic Non-Genetics 
Number of 
patients 
(percentage) 
GTC 
Number of 
patients 
(percentage) 
Age (years)   
0-3 46 (30.67%) 45 (30%) 
4-8 44 (29.33%) 38 (25.33%) 
9-12 22 (14.6%) 24 (16%) 
13-17 31 (20.67%) 24 (16%) 
18-21 7 (4.67%) 7 (4.67%) 
22+ 0 (0.0%) 12 (8%) 
Sex   
Male 71 (47.33%) 97 (64.67%) 
Female 79 (52.67%) 53 (35.3%) 
Race   
White 126 (84%) 138 (92%) 
Black 14 (9.33%) 7 (4.67%) 
Asian 6 (4%) 3 (2%) 
Not specified 4 (2.67%) 2 (1.33%) 
Insurance   
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Commercial (as primary or only) 84 (56%) 86 (57.33%) 
Medicaid (as primary or only) 65 (43.33%) 64 (42.67%) 
Self-pay 1 (0.67%) 0 (0.0%) 
Had secondary insurance 31 (20.67%) 38 (25.33%) 
Department   
Adolescent Medicine 1 (0.67%) 0 (0.0%) 
Allergy and Immunology 0 (0.0%) 11 (7.33%) 
Cardiology 1 (0.67%) 1 (0.67%) 
Child Advocacy 2 (1.33%) 0 (0.0%) 
Child Development Unit 7 (4.67%) 6 (4.0%) 
Diagnostic Referral 1 (0.67%) 0 (0.0%) 
Down Syndrome Clinic 1 (0.67%) 0 (0.0% 
Endocrinology 40 (26.67%) 15 (10.0%) 
Gastroenterology 3 (2.0%)  9 (6.0%) 
Hematology/Oncology 1 (0.67%) 7 (4.67%) 
Hepatology 1 (0.67%) 2 (1.33%) 
Nephrology 3 (2.0%) 5 (3.33%) 
Neurology 77 (51.33%) 83 (53.33%) 
Otolaryngology 8 (5.33%) 6 (4.0%) 
Pulmonology 1 (0.67%) 3 (2.0%) 
Rheumatology 3 (2.0%) 2 (1.33%) 
Total 150 (100%) 150 (100%) 
 
The number of diagnosis codes (ICD-10) associated with the appointment for each patient 
who completed genetic testing varied, with a mean of 1.46 ICD-10 codes for non-genetics patients 
and a mean of 1.37 ICD-10 codes for GTC patients (Table 5).  
 
 
 
 
 
 
 
 
Table 4 Continued 
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Table 5. ICD-10 code associated with visit 
ICD-10 Code category* Non-Genetics GTC 
Infectious Disease (A00-B99) 0 1 
Neoplasms (C00-D49) 1 3 
Hematologic Disorder (D50-D89) 1 6 
Endocrine, Metabolic Disease (E00-E90) 15 8 
Mental Disorder (F00-F99) 15 39 
Nervous Disease (G00-G99) 39 32 
Eye Disease (H00-H59) 2 1 
Ear Disease (H60-H95) 8 5 
Circulatory Disease (I00-I99) 1 1 
Respiratory Disease (J00-J99) 2 3 
Digestive Disease (K00-K93) 2 14 
Dermatologic Disease (L00-L99) 4 1 
Musculoskeletal Disease (M00-M99) 7 6 
Genitourinary Disease (N00-N99) 6 5 
Perinatal Condition (P00-P96) 2 0 
Congenital Disorder (Q00-Q99) 13 14 
Symptoms and Signs (R00-R99) 92 51 
Injury and Poisoning (S00-T98) 4 0 
Health Service Related (Z00-Z99) 5 15 
Total 219 205 
Note: Does not add to 150, due to the possibility of multiple diagnosis 
codes being associated with the visit 
*No appointments were associated with Pregnancy, puerperium (O00-
O96) 
 
 Finally, test orders were categorized into single gene, panel, exome, targeted familial 
sequencing, karyotype, FISH, chromosomal microarray, and Fragile X. The most common tests 
for non-genetics patients were panels (n=57), karyotype (n=37), single gene (n=30), chromosomal 
microarray (n=28), and FISH (n=23); 30 patients had two genetic tests performed at the same time. 
The most common tests for GTC patients were panel (n=70), chromosomal microarray (n=52), 
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Fragile X (n=14), and targeted familial sequencing (n=12); 13 patients had two genetic tests 
performed at the same time. The number of each kind of test ordered through non-genetics 
providers or through the GTC, with exomes excluded, was significantly different (p<0.0001). Post-
hoc analysis test of proportion (Bonferroni corrected p<0.007) identified that non-genetics 
providers were more likely than the GTC to order single gene tests (p=0.0007), karyotypes 
(p<0.0001), and FISH (p<0.0001); non-genetics providers were less likely than the GTC to order 
chromosomal microarrays (p<0.0001), Fragile X testing (p=0.0023) and targeted familial 
sequencing (p<0.0001); there was no statistically significant differences between ordering panels 
(p=0.253) between non-genetics providers and the GTC. Figure 1 outlines the types of tests 
ordered by department for non-genetics providers and Figure 2 outlines the types of tests ordered 
by referring department for GTC.  
Ad
ole
sce
nt 
Me
dic
ine
Ca
rdi
olo
gy
Ch
ild
 A
dv
oca
cy
Ch
ild
 D
eve
lop
me
nt 
Un
it
Di
agn
ost
ic 
Re
fer
ral
Do
wn
 Sy
nd
rom
e C
lin
ic
En
do
cri
no
log
y
Ga
str
oen
ter
olo
gy
He
ma
tol
og
y/O
nco
log
y
He
pat
olo
gy
Ne
ph
rol
og
y
Ne
uro
log
y
Ot
ola
ryn
go
log
y
Pu
lm
on
olo
gy
Rh
eum
ato
log
y
0.5
1
2
4
8
16
32
64
3
2
5
1 1
212
2
11 1 1 1
28
5
2
1
6
3
37
6
3
5
1 1
2
15
1 1 1
Ordering Department
N
um
be
r o
f T
es
t O
rd
er
ed
Single Gene
Panel
Karyotype
FISH
Chromosomal
Microarray
Fragile X
Figure 1. Genetic tests ordered by department for non-genetics providers 
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Figure 2. Genetic tests ordered by referring department for GTC 
 
3.3.2 Pre-Test Outcomes 
Of the 150 non-genetics patients’ charts, 76 (51%) had documentation of submission of 
prior authorization to insurance and date of insurance decision. Excluding federal holidays and 
weekends, the mean length of time from appointment to submission for non-genetics providers 
was 23 days (median 13 days) and the mean length of time from submission to approval for non-
genetics patients was 16 days (median 9.5 days). Of the 150 GTC patients’ charts, 123 had 
documentation of submission of prior authorization to insurance and date of insurance decision. 
The mean length of time from appointment to submission for the GTC was 15 days (median 11 
days) and the mean length of time from submission to approval for GTC patients was 11 days 
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(median 4 days). These lengths of time to submission and authorization are demonstrated in Figure 
3. The GTC had statistically significant shorter length of time from appointment to insurance 
submission compared to non-genetics providers (p=0.0068), but the difference for length of time 
from submission to approval was not statistically different (p=0.0927).  
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Figure 3. Box and whisker plot for length of time for submission to insurance and insurance approval 
 
 Similarly, non-genetics providers, compared to the GTC, were less likely to include 
language describing the medical necessity of the requested genetic test in their clinic note (20% vs 
100%, p<0.0001) and more likely to have insurance request a letter of medical necessity (LMN) 
(12% vs 1.3%, p=0.0001). The mean length of time from submission to insurance approval for 
non-genetics patients without medical necessity documented in the clinic note was 18 days 
(median 10 days), the mean length of time from submission to approval for non-genetics patients 
with medical necessity documented in the clinic note was 10 days (median 6 days), and the mean 
length of time from submission to approval for GTC patients (who all had medical necessity 
documented in the clinic note) was 11 days (median 4 days). The difference in length of time for 
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insurance approval between non-genetics providers who did and did not include LMN language in 
the clinic note is significant (p=0.03);however, non-genetics providers that did include LMN 
documentation had a similar length of time for insurance approval compared to the GTC (p=0.56). 
Of the non-genetics providers, no specialty which ordered genetic testing for multiple patients 
routinely included medical necessity language in their note. Neurology included medical necessity 
language in their note 19.5% (15/77) of the time and endocrinology included medical necessity 
language in their note 15% (6/40) of the time. Of the referrals to the GTC, 11.2% (23/206) 
attempted authorization for genetic testing prior to referral.  
 Previous genetic testing was completed for 12.67% (19/150) of the non-genetics patients 
and 18.44% (38/206) of the GTC patients. There was no redundant testing when comparing current 
test orders with previously completed genetic testing for both non-genetics patients and GTC 
patients.  
 Clinical utility was identified in the majority of tests selected for non-genetics patients 
(98.67%, 148/150), while only 58.67% (88/150) were determined to be the most appropriate test 
for the patient based on the 2017 CHP genetic testing formulary and patient symptoms. 
Consistency between coders for clinical utility was 98.67% (148/150) and for the most appropriate 
test for the patient was 82.67% (124/150). Of the high-volume specialties, neurology selected the 
most appropriate test for their patient 57% of the time and endocrinology selected the most 
appropriate test 72.5% of the time. Figure 4 displays the proportion of tests ordered by the non-
genetics providers that were the most appropriate test for the patient, by test type. The number of 
times each type of test is the most appropriate for non-genetics patients, with Fragile X excluded 
due to small sample size, was significantly different (p<0.0001). Post-hoc analysis test of 
proportion identified that chromosomal microarray (p=0.0025) is more likely to be the most 
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appropriate test, while single gene testing (p<0.0001) is less likely to be the most appropriate test. 
The majority of chromosomal microarrays (89%) and Fragile X (80%) orders were the most 
appropriate test for the patient; often, test orders of FISH (69.56%), karyotypes (67.57%), and 
panels (61.4%) were the most appropriate test for the patient; and rarely were single gene tests 
(10%) the most appropriate test for the patient. Relatedly, the GTC suggested modifications to test 
orders in 7.3% (15/206). Institution-preferred laboratories were utilized for all but one (99.3%, 
149/150) of genetic tests selected for non-genetics patients.  
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Figure 4. Proportion of tests that were the most appropriate for their patient by test selected 
 
 Pre-test counseling was categorized into documentation of discussion of risks, benefits, 
and limitations; the possible types of results; the possibility of incidental findings; and extent of 
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family history elicited. Definitions of these terms are above in Table 2. For documentation of 
discussion of risks, benefits, and limitations, the majority of non-genetics providers did not 
document any of these elements (74.67%, 112/150) and 23.3% (35/150) documented only one 
element. For documentation of the possible types of results, about half of non-genetics providers 
did not document any possibility (51.33%, 77/150) while the other half (44.67%, 67/150) 
documented one possibility. Almost none of the non-genetics providers included documentation 
of the possibility of incidental findings (0.67%, 1/150). Finally, the majority of non-genetics 
providers documented a targeted family history (56.67%, 85/150), while the remaining was almost 
evenly divided between no documentation of family history (20.67%, 31/150) and documentation 
of full family history (22.67%, 34/150). These data of pre-test counseling are presented in Figure 
5.  
None documented
One documented
Two documented
Three documented
Risks, benefits,
and limitations None documented
One documented
Two documented
Three documented
Types of results
Not documented
Documented
Incidental findings
No family history
Targeted family history
Full family history
Family history
A B
C D
Figure 5. Documentation of pre-test counseling by non-genetics providers 
A: Documentation of risks, benefits, and limitations. B: Documentation of types of results. 
C: Documentation of incidental findings. D: Documentation of family history 
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 Further analysis of pre-test counseling was completed for Neurology and Endocrinology, 
as they consisted of the majority of non-genetics providers test orders. The proportion of 
documentation of zero and one risk, benefit, or limitation between Neurology and Endocrinology 
providers was not statistically different (p=0.6469) and proportion of documentation of none, 
targeted, or full family history between these two departments was not statistically different 
(p=0.4542), while the proportion of documentation of zero and one types of possible results 
between these two departments was statistically different (p<0.0001).  
Finally, the GTC made referrals based on family history unrelated to the patient’s genetic 
test order 14.6% (30/206) of the time; this type of referral was made by none (0/150) of the non-
genetics providers.  
3.3.3 Post-Test Outcomes 
Non-genetics providers had 24 positive, 23 VUSs, two carriers, one pharmacovariant, and 
104 negative results. The GTC had 33 positive, 31 VUSs, two carriers, and 88 negative results. 
When comparing positive, negative, and VUS results, the non-genetics patients and GTC patients 
did not have significantly different results (p=0.1285). The genetic testing results are presented in 
Figure 6. Because an individual can have more than one result, the total number of results is 
greater than 150.  
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Figure 6. Genetic testing results by type of test and non-genetics or GTC 
 
Parental VUS testing was discussed (as determined by clinic note or “phone messages” 
documentation), but not necessarily completed, with the family for all non-genetics patients 
(15/15) and all (18/18) GTC patients when the patient had a VUS warranting follow-up (either in 
an autosomal dominant condition, a cytogenetic change, and/or if the lab recommended free 
parental testing). Parental testing did not yield reclassification of the variant for any of the patients. 
Details of parental testing is outlined in Table 6 
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Table 6. Parental testing upon proband VUS result 
Outcome Non-Genetics GTC 
VUS in AR gene  11 
VUS in AD gene or cytogenetic, or  
Two VUSs in an AR gene 
16 20 
Parental testing performed 8 8 
Inherited  7 7 
De novo 0 0 
Not determined (one parent tested 
negative, other parent not tested) 
1 1 
Parental testing pending 0 3 
Parental testing not performed 8 9 
Biological parents not available 4 2 
Proband lost to follow 0 3 
Parent appointment issue 1 0 
Parental testing not free 3 0 
Parents declined testing 0 2 
Parental testing not recommended by 
lab  
0 2 
Total VUSs identified 24 31 
 
 Referrals to medical genetics or neurogenetics were made upon completion of genetic 
testing for 21.22% (32/150) non-genetics patients and 28% (42/150) GTC patients. This difference 
is not statistically significant (p=0.2279).  
3.3.4 Relationship Between Variables 
Whether the non-genetics provider ordered the most appropriate test for the patient or not 
was not significantly associated with different test result of positive, negative, or VUS (p=0.6996). 
Furthermore, of the eight patients where test orders were modified after GC input in the GTC, one 
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result (1/8, 12.5%) was positive, but this gene was included on the smaller, original panel 
requested; two (25%) were VUSs and five (62.5%) were negative.  
 Multiple linear regression modeling, used to predict whether the patient’s age, sex, race, 
insurance type, if they have secondary insurance, and if the test was ordered through non-genetics 
providers or the GTC are related to the length of time from the appointment to when insurance 
authorization is submitted. The model showed that the mean time from appointment to insurance 
authorization submission is 11.78 days for the GTC and is 11.78 + 8.34 days for non-genetics 
providers.  
In order to assess whether the patient’s age, sex, race, insurance type, if they have 
secondary insurance, if the test was ordered through non-genetics providers or the GTC, if the 
provider’s note included LMN language, and if insurance requested LMN language are related to 
the length of time from insurance authorization submission to insurance decision, a multiple linear 
regression model was used. The model showed that the mean time from insurance authorization 
submission to decision is 16.73 days, and was related to race (13.48 days longer for black patients), 
insurance type (10.19 days faster for patients with commercial insurance), if they have secondary 
insurance (8.89 days longer for patient who had secondary insurance), and if the insurance 
company requested an LMN (20.14 days longer if insurance requested an LMN).  
A multinominal logistic regression model was used to assess whether the patient’s age, sex, 
or race, if the patient had previous genetic testing completed, the type of genetic test ordered, if 
the test was the most appropriate test for the patient, and if the test was ordered through non-
genetics providers or the GTC are related to the genetic test result. The model showed that 
microarray results are less likely to be positive and panels are more likely to have a VUS result.  
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In order to assess whether the patient’s age, sex, or race, the type of genetic test ordered, if 
the test was ordered through non-genetics providers or the GTC, what department was the 
ordering/referral department, and the genetic test result are related to if there is a medical genetics 
or neurogenetics referral, a multinomial logistic regression model was used. The model showed 
that the referrals to medical genetics or neurogenetics is significant only for individuals who 
received microarray testing and negative results.  
3.3.5 Genetic Testing Ordering Practices 
In 2016, approximately two-thirds of genetic testing completed at CHP was ordered 
without a genetics professional. However, in 2018, three-quarters of genetic testing completed at 
CHP was ordered with a genetics professional.  
3.4 Discussion 
3.4.1 Pre-Test Outcomes 
There were many significant benefits in pre- genetic testing outcomes when patients had 
genetic testing completed in the GTC compared to those completed by non-genetics providers. 
This is due to the unique training of GCs and the dedicated appointment time in the GTC to review 
the intricacies of genetic testing.  
First, the types of genetic tests ordered was significantly different between non-genetics 
providers and the GTC, with single gene tests, karyotypes, and FISH were more commonly ordered 
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by non-genetics providers, chromosomal microarrays were more commonly ordered in the GTC, 
and panels and Fragile X testing to be ordered approximately the same amount by non-genetics 
providers and the GTC. Tests more often ordered by non-genetics providers are simpler and have 
been available for longer, compared to those ordered more often by the GTC. These simpler tests 
often use older technology and represent an antiquated test selection process, possibly representing 
non-genetics providers not being up to date in current genetic testing guidelines or methodology. 
This explanation is supported by Baars et al., which identified that non-genetics providers would 
benefit from continuing education in genetics topics, and Klitzman et al., which identified that 
non-genetics providers will order genetic testing, even if they report not being comfortable with 
their knowledge in genetics (Baars et al., 2005; Klitzman et al., 2013). However, another 
explanation for the simpler tests ordered by non-genetics providers could be that they ordered 
genetic testing for narrow indications that can be identified through these methodologies (such as 
wanting to prescribe Depakote and pursuing POLG sequencing or suspicion for Turner syndrome 
and pursuing a karyotype and FISH for sex chromosomes),and referred broader indications and 
differential diagnoses to medical genetics to pursue more complex genetic testing.  
The length of time from appointment to insurance pre-authorization submission was 
significantly quicker for GTC patients compared to non-genetics patients. This may be explained 
by the dedicated insurance authorization specialists utilized by the GTC and that some non-
genetics providers waited for completion of routine lab tests before pursuing genetic testing, weeks 
to months after the appointment. Obtaining insurance pre-authorization for genetic testing is often 
a complicated process, and specific workflows by CHP Genetics Department and other institutions 
have been implemented in order to streamline this process (Uhlmann et al., 2017). Non-genetics 
departments may have a sub-par system to handle the complexities of genetics pre-authorizations. 
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However, data for when the provider decided to pursue genetic testing was not captured and 
assumes it is the date of the appointment. During data collection, it was noted many times by non-
genetics providers that they pursued genetic testing weeks or months after the appointment upon 
receipt of lab work or other clinical information, but this data was not captured or assessed, limiting 
the impact of this finding.  
The length of time from insurance pre-authorization submission to insurance approval was 
not significantly different for non-genetics patients compared to GTC patients. Insurance 
companies often have a standard operating procedure for pre-authorization of genetic testing, 
explaining this consistency. However, for non-genetics patients, there was a significantly longer 
length of time if the insurance company requested LMN language. This is likely due to the extra 
time needed to notify the provider of the need of an LMN, have the provider write and submit the 
LMN, and the insurance company to then review the LMN. Rates of insurance authorization were 
not assessed as this was a study of genetic testing completed.  
Non-genetics providers attempted insurance pre-authorization 11.3% (17/150) of the time 
before referring to the GTC to aid in obtaining pre-authorization. Some insurance companies now 
require genetic counseling prior to certain or all genetic testing (Cigna, 2016; UnitedHealthCare, 
2015; UPMC Health Plan, 2018). The GTC can mitigate this barrier, as they offer same day 
appointments, thus not requiring a separate trip to the hospital to coordinate genetic testing, 
without which could cause a patient to become lost to follow- up. However, the study did not 
assess if the original genetic test order was denied due to lack of GC involvement, lack of medical 
necessity language, or any other factor.  
It is standard practice for the GTC to include LMN language in their clinic note, while the 
minority of non-genetics providers included LMN language in their note. This could be due to the 
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genetic tests they order often do not require insurance pre-authorization (such as karyotypes), they 
send for insurance pre-authorization without an LMN, they submit an LMN separate from the 
clinic note (and not documented in the EMR) for insurance pre- authorization, or they do not 
understand the importance of including this information. During chart review, the latter, where the 
non-genetics provider mentions submitting an LMN that was not included in the EMR, was 
observed multiple times but was recorded as no LMN documented. Definitions of LMN vary by 
insurance companies, but general themes, as determined by Capasso, are clinical validity of the 
test, the individual is appropriate to test based on present symptoms or risk to develop symptoms, 
and how the genetic testing results will impact medical management and treatment of the patient 
(Capasso, 2014). While the former two are important, the latter is especially imperative to be 
documented in the EMR to allow for documentation of how the test results will impact care of the 
patient.  
Clinical utility was identified and institution-preferred lab was used in nearly all of test 
selection for non-genetics patients, but about two-fifths did not have the most appropriate test 
selected. This could be explained by the limited clinical review performed in this study or lack of 
updated knowledge in genetic testing selection. For example, if a patient has intellectual disability, 
a karyotype does have clinical utility, but the most appropriate test for that patient would be a 
microarray; however, prior to microarrays, a karyotype may be the most appropriate test. 
Therefore, non-genetics providers have outdated knowledge or workflows related to genetic 
testing, they may make test selections that have some clinical utility but are not the most 
appropriate test. Continuing education, as suggested in the literature, can help keep non-genetics 
providers up to date on current testing strategies (Baars et al., 2005; Guttmacher et al., 2007). 
However, the proportion of tests that were most appropriate for the patient may be skewed to 
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appear more correct due to the insurance review process. If a non-genetics provider ordered a test 
that overtly is not appropriate, it is likely that insurance would decline that inappropriate test. 
Previous studies have improved or modified genetic test selection in 5-32% of laboratory-initiated 
processes and 13-25% of institution-initiated processes (Dickerson et al., 2014; Londre et al., 2017; 
Mathias et al., 2016; C. E. Miller et al., 2014; Suarez et al., 2017; Wakefield et al., 2018). The 
41.33% of genetic tests that were not the most appropriate for non-genetics patients is higher than 
what the literature reports. While these test orders were not modified due to the retrospective 
methodology of this study, the higher rate of possible test modification could represent more 
genetic test education needed by non-genetics providers at CHP, more stringent UM review by the 
GTC compared to other studies, or the rate could be similar to previous studies if non-genetics 
providers were given the opportunity to cancel testing upon UM review. Relatedly, the GTC 
suggested UM modifications to test orders in 5.33% of patients. This finding is lower than what 
other institution-initiated genetic UM review processes report. This may be reflective of recent 
educational grand rounds about genetic testing that may have improved knowledge between 2017 
and 2018, the possibility that non-genetics providers at CHP who know about the GTC make better 
genetic test selections, the UM review at the GTC was performed for all tests ordered through this 
particular service delivery model, while other programs in the literature perform UM review of 
genetic testing ordered through a specific service delivery model, have a monetary cutoff, or other 
criteria, the majority of genetic tests ordered for the GTC were chromosomal microarrays which 
is a first tier test and often the most appropriate, or because the GTC triaged medically complex 
patients to Medical Genetics clinic where more UM test selection was not reviewed. Finally, while 
previous genetic testing was completed for some non-genetic and GTC patients, none had 
redundant testing. Redundant testing differs from duplicate testing, in redundant testing is 
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repeating a small part of a test that has already been performed, but may be called something 
different (such as a chromosomal microarray and a FISH, or a panel and a single gene that is 
included on the panel). Duplicate testing is often assessed in UM review, and 0% duplicate testing, 
in addition to 0% redundant testing, is better than the 1-3% of duplicate testing and 10% redundant 
testing reported in the literature (Riegert-Johnson et al., 2008; Suarez et al., 2017).  
Documentation of pre-test counseling and assessment done by non-genetics providers is 
worse than what is typically done in appointments by GCs in the GTC. For risks, benefits, and 
limitations, almost all of non-genetics providers only documented one aspect (23.3%) or did not 
document any (74.67%) risks, benefits, or limitations. Similarly, almost all non-genetics providers 
documented only one possible type of result (44.67%) or did not document any possible types of 
results (51.33%). Finally, almost none (0.67%) of the non-genetics providers documented the 
possibility of incidental findings. Documentation of the possibility of secondary findings was not 
assessed, as secondary findings are most often associated with whole exome or genome 
sequencing, which is only available at CHP through subspecialty clinics such as Medical Genetics 
or Neurogenetics. While there is no literature assessing pre-test counseling performed by non-
genetics providers or the extent of medical school education on pre-test counseling (Thurston et 
al., 2007), there are practice guidelines that support non-genetics providers ordering appropriate 
genetic testing and recommend communicating the risks, benefits, and limitations of the test and 
the possible types of results to the patient (Satya-Murti et al., 2013). These guidelines also mention 
that if the non-genetics provider does not have enough knowledge or comfort with genetics, they 
should refer to a GC or other qualified health care provider to counsel the genetic test offering 
(Satya-Murti et al., 2013). 
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Regarding documentation of family history, non-genetics providers often (56.67%) had a 
targeted family history and some (22.67%) had documentation of full family history; about one-
fifth (20.67%) did not have any documentation of family history. Many organizations support the 
provider taking a comprehensive, three generation family history (American College of 
Obstetricians and Gynecologists Committee on Genetics, 2011; American Medical Association, 
2004; Rich et al., 2004; Wattendorf & Hadley, 2005); however, the majority of providers in this 
study only documented a targeted family history. There is no literature supporting a limited family 
history over a full family history; however, non-genetics providers tend to opt for limited family 
history relevant to the patient’s chief complaint. This could be due the increased amount of time 
required to take a comprehensive family history and lack of education or training on the benefits 
to taking a full family history, Thorough family history assessment that could identify other risk 
factors, as represented by the 14.6% of patients in the GTC who received referrals for unrelated 
family history. To aid appropriate referrals upon comprehensive family history assessment, 
ACMG and NSGC developed guidelines for non-genetics providers on when to refer to a GC 
(Hampel et al., 2015; Pletcher et al., 2007).  
 Finally, further analysis of documented pre-test counseling was performed between 
Neurology and Endocrinology. There were no significant differences in documentation of risks, 
benefits, and limitations, or documentation of family history, however there was a significant 
difference of documenting zero or one type of possible results, with endocrinology more likely to 
document one type of possible result. This is likely due to endocrinology often ordering karyotypes 
for limited indications, such as Turner Syndrome or Klinefelter Syndrome, which counted as 
documentation of one type of result, and neurology ordered panels or microarrays for broader 
indications such as epilepsy or autism, where a specific differential diagnosis is not suspected.  
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Upon completion of comprehensive family history assessment, GCs in the GTC made a 
referral for unrelated family history for 14.6% of patients. This is similar to the 21% (88/416) of 
prenatal genetic counseling patients that GCs identified an adult or cancer GC referral 
(McClatchey et al., 2018), as comprehensive family history assessment is a core duty of a GC 
(Resta et al., 2006). By making appropriate referrals, families understand how genetics plays a role 
not only in their child’s primary indication for genetic testing, but also how genetics can explain a 
family history of cancer or cardiac involvement. These referrals can identify families at high risk 
for certain health implications and may have a pathogenic variant in one of the ACMG 59 genes, 
which are present in approximately 1-3% of the healthy population (Haffty et al., 2009; Olfson et 
al., 2015).  
This study highlights the benefits of the GTC, including thorough pre-test counseling, 
comprehensive family history assessment, and UM review. By increasing access to quality 
genetics care, the GTC improves patient care by ensuring proper informed consent, providing 
appropriate follow-up, and completing the most appropriate genetic testing. A similar service 
delivery model that combined consultative services and UM review has shown great success on 
improving provider ordering practices (Suarez et al., 2017).  
3.4.2 Post-Test Outcomes 
There were no significant differences in the post-genetic testing outcomes assessed in this 
study between patients who had genetic testing completed through a non-genetics provider and the 
GTC. However, the GTC does offer post-test counseling, which is a valuable resource to aid in 
understanding of genetic testing already completed.  
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Genetic testing results were statistically similar between the two groups. While it might be 
expected that there is a higher diagnostic yield using the UM GTC clinic, this could be explained 
by both groups of patients not being as medically complex and the varying diagnostic yield of 
genetic testing technology. Literature reports the diagnostic yield of a chromosomal microarray, 
when used as a first tier test for individuals with developmental disabilities or congenital 
anomalies, to be 15-20% (D. T. Miller et al., 2010), however, the diagnostic yield of the microarray 
for non-genetics and GTC patients was 10.7% and 9.6%, respectively. The diagnostic yield in both 
clinics being lower than reported could be due to patients not being as medically complex as 
Medical Genetics patients.  
Uptake of parental VUS testing was also statistically similar between non-genetics patients 
and GTC patients. While there is no literature on follow up parental testing when recommended 
for VUS resolution in a proband, it was reassuring that the non-genetics patients had similar 
outcomes to the GTC patients. However, both groups of patients had biological parents that were 
not available and patients that were lost to follow up, phenomena that are reasonable and within 
normal limits, decreasing the uptake of parental VUS testing. For the GTC, 9.7% of VUS patients 
were lost to follow-up. Conversely, 16% of non-genetics patients and 6.4% of GTC patients with 
VUSs did not have biological parents available. Of note, laboratories did not recommend parental 
VUS testing for two non-genetics patients and two GTC patients who had a VUS in an autosomal 
dominant gene or in cytogenetic region. For the GTC patients, both also had a pathogenic variant 
that was explanatory for the phenotype.  
Finally, referral rates to Medical Genetics and Neurogenetics were statistically similar. 
This is expected, given the study design to look at comparable populations and the statistically 
similar genetic test results between the two groups. By referring to Medical Genetics or 
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Neurogenetics, the provider allows the patient to receive a more comprehensive evaluation and 
management of care.  
3.4.3 Relationship Between Variables 
Genetic testing results for non-genetics patients who did have the most appropriate genetic 
test did not significantly differ from those who did not have the most appropriate genetic test. 
There are several possible explanations for this result. First, because this is an assessment of 
genetic testing completed, insurance likely denied genetic test selection that had no utility or was 
grossly inappropriate. Additionally, appropriateness was determined by UM GCs, who take in 
account cost effectiveness and contract pricing with laboratories, meaning that the most 
appropriate test could be a similar panel that offered more genes. Finally, the additional genes on 
broader panels likely represent a minority of diagnoses compared to the original genes on smaller 
panels. Therefore, a minor increase in diagnostic yield would be expected with broader panels, but 
may not have been appreciated in this small sample size.  
While the GTC did offer test modification to 14.6% of patients, only eight of them 
completed genetic testing, and only one of those were positive. Therefore, increased diagnostic 
yield due to UM modification cannot be assessed due to the small sample size; however, UM 
modification can yield cost savings, though this was not studied.  
No demographic factors were found to be associated with length of time from appointment 
to insurance authorization in regression modeling, as the only significant result was non-genetics 
providers taking about 8 more days to submit for insurance authorization, as previously identified 
in pre-test outcome assessment.  
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 Regression modeling to predict length of time from insurance authorization submission to 
approval did yield informative results. First, approval took approximately 13 days longer for black 
patients. This difference is unexpected and could reflect disparities in healthcare or could be due 
to the groups being inherently different. Second, insurance approval was about 10 days faster for 
patients with commercial insurance. This could be due to commercial insurance companies having 
more resources for authorization processes compared to government issued insurances. Third, 
approval for patients with secondary insurance was about nine days longer than those without it. 
Due to the way data were captured as the length of time from insurance authorization submission 
to approval was defined as length of time from initial insurance authorization submission to final 
approval. Therefore, if the patient’s primary insurance denied the genetic test, and the provider 
then submitted to secondary insurance that approved the genetic testing, the back-and-forth 
between insurance companies was included in the time assessment. Finally, approval took about 
20 days longer if the insurance company requested an LMN. Again, this is likely reflective of the 
back-and-forth interactions between the provider and the insurance company. This highlights the 
importance of including LMN language in the clinic note, which the GTC always does.  
Regression modeling to predict genetic testing result provided significant results consistent 
with the literature. First, chromosomal microarray testing is less likely to yield a positive result. It 
is a first-tier test for individuals with developmental delay or multiple congenital anomalies, due 
to the cost-effective nature of its diagnostic yield, with a diagnosis being identified approximately 
10-20% of the time. This diagnostic yield in the literature is similar to the 10.1% (8/79) in this 
study (Rehder et al., 2013; Tammimies et al., 2015). Second, multigene panels are more likely to 
yield a VUS. Given that VUS rates for panels range from one percent per gene analyzed to 7-52% 
in cancer panels (van Marcke et al., 2018), a high likelihood for a VUS result is expected and 
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consistent with what was identified in this study. Finally, an increase in patient age is less likely 
to have a positive genetic testing result.  
The last regression model was performed to predict referrals to Medical Genetics or 
Neurogenetics. It was significant for chromosomal microarray more likely to receive a referral and 
negative results less likely to receive a referral. Patients who have developmental delay or multiple 
congenital anomalies should not only have chromosomal microarray as the first-tier test, they also 
should receive a thorough evaluation by a geneticist/dysmorphologist as they can suggest further 
testing if the microarray is negative or guide management if the microarray is positive. Patients 
who receive a negative test result were less likely to receive a referral for a genetics evaluation. 
While a geneticist might offer further testing for these patients, many providers ordered genetic 
testing to rule out a specific genetic condition, with plans to continue to care for the patient based 
on their presenting features and symptoms; however, an evaluation by a medical geneticist could 
still be beneficial in care management. 
3.4.4 Case Example Vignettes  
Many times, the most appropriate test was not selected by the non-genetics provider, both 
when ordering in 2017 and when referring to the GTC in 2018. While test modification was not 
possible for non-genetics providers’ orders in 2017 due to the retrospective chart review nature of 
this study, alternative testing strategies were discussed upon data collection.  
3.4.4.1 Non-Genetics Providers 
An endocrinologist wanted to test for Prader-Willi Syndrome (PWS). The provider ordered 
a PWS FISH test which was negative; however, FISH will only identify about 65% of patients 
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with PWS. Instead, an MS-MLPA test that assesses for methylation aberrations will be able to 
identify 99% of cases, making it a more appropriate test to order.  
A neurologist wanted to provide genetic testing for an infant with epilepsy. The family 
history was also significant for infantile epilepsy. While the provider did order an infantile epilepsy 
panel, GC UM review suggests that a more comprehensive epilepsy panel would be more 
appropriate. This is because genes on the more comprehensive panel can still present in infancy 
and if the infantile epilepsy panel was negative, it would be difficult to get a more comprehensive 
test approved later.  
A nephrologist evaluated a patient where Focal Segmental Glomerulosclerosis (FSGS) was 
on the differential, so the provider ordered a FSGS panel; however, the provider also wanted to 
assess APOL1, which was not included on the panel, so they ordered a single gene test in addition 
to the panel. A more cost-effective choice would be to identify a panel that included all the genes 
the provider wanted to assess or create a panel if one does not exist.  
Finally, a neurologist evaluated a male who has autism, developmental delay, starring 
spells, and large ears. The provider ordered a karyotype, which was negative; however, a 
chromosomal microarray is the first tier test for individuals with autism (D. T. Miller et al., 2010). 
Additionally, at CHP, Fragile X is often ordered in conjunction with chromosomal microarrays 
when the indication is Autism or developmental delay.  
3.4.4.2 GTC 
A patient with photogenic epilepsy, autistic features, and developmental delay, and had a 
normal oligoarray was referred to the GTC. The referring neurologist selected a comprehensive 
epilepsy panel (127 genes); however, an expanded epilepsy panel (1300) genes was suggested by 
the UM GCs as this test offers a broader scope at a similar price.  
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Otolaryngology referred a patient with bilateral sensorineural hearing, with a family history 
significant for hearing loss. The provider suspected Pendred Syndrome and selected a Pendred 
Syndrome panel. However, given that the family history does not reflect the autosomal recessive 
pattern of inheritance consistent with Pendred Syndrome, the UM GC suggested a broader hearing 
loss panel that could identify more diagnoses with a broader range of presentations.  
A patient was referred by neurology for a SNP microarray, PWS methylation, and Fragile 
X. Given that a SNP microarray can detect about 70% of PWS as well as many other diagnoses, 
the provider agreed with the UM GCs suggestion to pursue a SNP microarray and Fragile X, then 
refer to Medical Genetics upon a negative result.  
Finally, the UM GCs partnered with Gastroenterology providers to develop a custom 
pancreatitis panel that included all the desired genes at a reasonable contracted price with the lab. 
By doing this, they created the most appropriate test, based on utility of genes and cost, instead of 
having to pursue subpar panels or sequential testing that could increase cost and delay diagnosis.  
Through UM review, the GTC model allows for the most appropriate genetic test to be 
ordered for each patient. The UM formulary at CHP accounts for cost-effectiveness and clinical 
utility of the test, Therefore, healthcare dollars are spent more appropriately and patients are 
receiving the most relevant genetic testing due to the GTC’s UM review.  
3.4.5 Study Limitations 
While this study has assessed the benefits of a novel genetic counseling service delivery 
model not characterized in the literature, it is limited by the retrospective chart review 
methodology. The analysis heavily relies on assessment of what is documented in the patient’s 
EMR; however, EMR templates can include documentation of events that did not occur with the 
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patient or conversely, everything that did occur with the patient may not have been documented in 
the EMR. This limitation was especially noticed when assessing the length of time from 
appointment to submission of insurance pre-authorization, and from submission to authorization, 
as this was only documented in about half of non-genetics patient’s charts. However, there are 
likely other aspects of this study not documented or documented erroneously, such as discussion 
of informed consent. Problems and errors with EMR documentation and the use of templates is 
not unique to CHP, as it has been studied numerous times in the literature and can cause liability 
issues (Bowman, 2013; Zahabi et al., 2015).  
Similarly, this study had to simplify the definitions of informed consent, documentation of 
family history, and LMN language. For aspects of informed consent and LMN language, very 
specific language had to be documented in the clinic note to count as documentation; however, it 
is possible these variables were documented without that phrasing. For family history, the 
definition of a full family history specific did not include “a three-generation pedigree”, as GCs 
tend to be the only providers that utilize this methodology. Instead, the definition “documentation 
of the presence or absence of the patient’s phenotype, or related symptoms, in family members, 
and documentation of unrelated medical concerns in third degree relatives” was used. This 
definition would count a patient with Autism as an indication, with documented family history of 
a grandparent with hearing loss as a full family history, when other family history aspects, such as 
cancer, were possibly not fully assessed and documented.  
Additionally, this study assessed genetic testing outcomes in patients that completed 
genetic testing. Further assessment of those where genetic testing was ordered, but not completed 
due to insurance denial, change of mind, etc. would be beneficial to the literature to understand 
differences between patients who do not complete genetic testing when it is ordered and those who 
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do. It would also be helpful to better understand if there are any pre-test outcomes or differences 
between non-genetics providers and the GTC that can explain these differences. It is possible for 
there to be higher rates of insurance denial in non-genetics providers compared to the GTC due to 
inappropriate test selection, and this in addition to rates of patients choosing to move forward with 
genetic testing would be interesting to study.  
Further, this study focused on genetic testing completed for non-genetics patients in 2017 
and GTC patients in 2018. This was due to the assumption that non-genetic providers can refer to 
the GTC in 2018, so the population of patients who receive genetic testing would be comparable. 
However, patients who had genetic testing completed through non-genetics providers in 2018 were 
not assessed. Perhaps they were not referred to the GTC due to the routine nature of genetic testing, 
the provider’s familiarity with genetic testing, or the provider was unaware of the GTC. However, 
further assessment of genetic testing not completed through the GTC (or with the aid of a genetics 
provider) could identify if there are gaps in the GTC’s service delivery model and assess current 
genetic testing ordering practices by non-genetics providers.  
Finally, this study was performed on a limited sample at one institution, making the results 
non-generalizable to other institutions, especially as this is a novel service delivery model. Further 
studies can assess differences in genetic testing outcomes between non-genetic providers and 
genetics providers at other institutions.  
3.4.6 Future Directions 
Future studies should continue to assess differences in genetic testing outcomes between 
non-genetic patients and genetic patients. As genetic testing is becoming both more commonplace 
and complex, understanding current genetic testing ordering practices and procedures by non-
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genetics providers can allow for appropriate interventions by genetics professionals, including 
providing or creating educational resources, consulting services, standard operating procedures, 
formulary review, and new service delivery models, as determined by the needs of the institution 
and its patients. Based on the current success of the GTC and these results highlighting the success, 
the GTC is setting up satellite clinics and UPMC aims to create a similar model for adult clinics.  
Additionally, patient satisfaction was not assessed in this study. It would be worth 
understanding if patients who receive comprehensive pre-test counseling by the GTC have higher 
satisfaction and understanding of results, compared to if genetic testing is ordered by the non-
genetics provider, with whom they may have a long standing relationship.  
3.5 Conclusion 
The GTC is a novel service delivery model in that it provides UM; access to genetic 
counseling in a timely manner for routine and uncommon (but not medically complex) indications; 
comprehensive family history assessment; and a resource for non-genetics providers. The study 
found that the GTC provides significant benefit in pre- genetic test outcomes, including pre-test 
counseling, comprehensive family history assessment, UM for appropriate test selection, and a 
faster time from appointment to insurance pre-authorization submission, to patients. While the 
GTC does not have any significant differences in post-tests outcomes for patients undergoing 
genetic testing, it is available for post- genetic test counseling, which can be beneficial to the 
patient and provider, but was not assessed in this study. Other institutions should consider adoption 
of a service delivery model similar to the GTC to aid the genetic testing process, improve UM, and 
increase access to GCs.  
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4.0  Research Significance to Genetic Counseling and Public Health 
Genetic testing is an expanding field that accounts for a significant amount of our 
healthcare dollars (UnitedHealth Center for Health Reform and Modernization, 2012). Genetic test 
results can be informative for treatment, management, and understanding of recurrence risk 
(Uhlmann et al., 2009). Furthermore, understanding the etiology of a disease or risk to manifest 
certain symptoms is imperative for early interventions, such as providing supportive therapies, 
increasing cancer surveillance, offering prenatal testing, prescribing different medications, or 
facilitating cascade testing. These interventions can be cost-saving to the healthcare system overall 
(D'Andrea et al., 2015). Therefore, it is a public health importance that the most appropriate genetic 
test is ordered for the patient.  
However, the impact of genetic testing is only as good as the provider’s understanding of 
genetic testing and the patient’s access to genetic testing. Due to the increasing proportion of non-
genetics providers ordering genetic testing, more inappropriate genetic testing is being ordered and 
less patient education is occurring (Armstrong et al., 2015; Baars et al., 2005; Bensend et al., 2014; 
Diamonstein et al., 2018; Greendale & Pyeritz, 2001; Guttmacher et al., 2007; Harvey et al., 2007; 
Hofman et al., 1993; Klitzman et al., 2013; McGovern et al., 2003; Salm et al., 2014; Thurston et 
al., 2007). While many hospital systems and laboratories have implemented utilization 
management (UM) programs to aid test selection, which afforded significant cost savings and 
improved patient care, these programs do not necessarily increase access to genetic testing or 
genetic counseling (Anderson et al., 2012; Dickerson et al., 2014; Kotzer et al., 2014; Londre et 
al., 2017; Mathias et al., 2016; C. E. Miller et al., 2014; Riegert-Johnson et al., 2008; Riley et al., 
2015; Suarez et al., 2017; Wakefield et al., 2018). 
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Access to genetic testing, with quality genetic counseling to understand the implications of 
genetic testing, has increased at Children’s Hospital of Pittsburgh, due to the recently implemented 
Genetic Testing Clinic (GTC). The GTC incorporates both UM and comprehensive genetic 
counseling services to provide both appropriate genetic test selection and thorough informed 
consent to non-genetics providers’ patients. This study highlighted the benefits to genetic testing 
ordered with the aid of the GTC compared to when it is ordered by a non-genetics provider. These 
benefits include utilization management, comprehensive family history assessment, thorough pre-
test counseling, and the availability of post-test counseling. The GTC improves access to quality 
genetic counseling and ensures proper test selection – both of which are imperative to public 
health.  
The Centers for Disease Control and Prevention (CDC) recognize 10 essential public health 
services (Center for Disease Control and Prevention, 2018). While this research incorporates all 
aspects of the 10 essential public health services, it especially addressed the “evaluation of 
effectiveness, accessibility, and quality of personal and population-based health services” (Center 
for Disease Control and Prevention, 2018). As the GTC is a new service delivery model, it was 
important to assess its benefits and possible limitations compared to genetic testing ordered by 
non-genetics providers.  
This study highlights a novel service delivery model for genetic counseling services that 
incorporates UM. This service delivery model can be adopted or modified in other healthcare 
institutions to provide cost savings and increase patient care. Additionally, this study identified 
domains to modify protocols or increase education for non-genetics providers and their genetic 
testing ordering practices. These interventions will also allow for more appropriate test selection 
and provide quality patient care.  
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5.0  Public Health Essay: The Nuances of CPT® Coding for Multigene Panel Tests 
5.1 Background 
5.1.1 Insurance in the U.S. 
Healthcare in the U.S. has been shaped by the private insurance market, with government 
sponsored insurance covering select populations (Starr, 2011). Insurance in the U.S. is complicated 
and is ever-evolving, but put simply, private insurance is purchased through an individual’s 
employer or independently, providing insurance for individuals and families; Medicaid is a 
government sponsored program, providing insurance to individuals with low income or 
disabilities; and Medicare is a different government sponsored program, providing insurance to 
those over the age of 65. Kaiser Family Foundation (KFF) offers a comprehensive review of how 
insurance works, including the role of private insurance, Medicaid and its expansion through the 
Affordable Care Act (ACA), and Medicare (Antonisse et al., 2018; Kaiser Family Foundation, 
2008, 2013, 2019). KFF also has a glossary of insurance related terms as well as a guide to 
understanding health insurance (Kaiser Family Foundation, n.d.-a, n.d.-b). 
As opposed to universal healthcare in other Western countries, insurance in the U.S. is 
variable from plan to plan and can leave patients with a significant bill even when insured. The 
ACA mandated all insurance companies provide coverage for ten essential health benefits, 
including ambulatory patient services; emergency services; hospitalization; pregnancy, maternity, 
and newborn care; mental health and substance use disorder services; prescription drugs; 
rehabilitative and habilitative services and devices; laboratory services; preventive and wellness 
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services and chronic disease management; and pediatric services, including oral and vision care; 
however, additional services may be covered by the insurance company ("The Patient Protection 
and Affordable Care Act (PPACA)," 2010). Despite certain services being covered by an 
individual’s insurance, patients are often responsible for out-of-pocket costs, in addition to the 
premium, due to co-insurance, co-pay, deductible, and/or the service being provided at an out-of-
network facility.  
5.1.1.1 Insurance and Genetic Testing 
Genetic testing accounts for a significant portion of healthcare spending in the United 
States, and often provides incredibly valuable information for both medical professionals and 
families (UnitedHealth Center for Health Reform and Modernization, 2012). Informative genetic 
testing can guide healthcare management, allow for reproductive decision making, and provide an 
explanation for a health concern. However, genetic testing is not always a covered insurance 
benefit, and some insurances will only cover certain genetic testing. Prior authorization is often 
recommended or required to verify if genetic testing is a covered benefit.  
To approve genetic testing, insurance companies typically require genetic testing results to 
impact medical management (such as medication change, reproductive decision making, etc.) 
(Aetna, 2019; BlueCross BlueShield of North Carolina, 2019). Insurance companies may have 
additional requirements, such as genetic counseling or the patient being at reproductive age, in 
order to authorize genetic testing (Aetna, 2019; Cigna, 2016; UnitedHealthCare, 2015; UPMC 
Health Plan, 2018). Therefore, it is imperative to include all appropriate information, often via a 
letter of medical necessity (LMN), when submitting for insurance authorization for genetic testing.  
LMNs typically include patient’s demographic and insurance information, provider and 
clinic information, the patient’s ICD diagnoses, the name of the genetic test and laboratory it is 
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performed at, the genes included on the test, the CPT® code(s) associated with the test, and how 
the genetic testing results impact medical management (Uhlmann et al., 2017). These aspects of 
LMNs can be combined in conjunction with the clinic note and shared templates can be created to 
reduce the amount redundant work performed by the healthcare provider (Uhlmann et al., 2017).  
GCs recognize the important role insurance plays in genetic testing. Genesurance is a 
recently coined term referring to the “portion of a genetic counseling session, whether intentional 
or non-intentional, that is devoted to the topic of costs and insurance/third party coverage 
(particularly for genetic testing)” (Brown et al., 2018). Research has examined both GC and patient 
perspectives of genesurance (Brown et al., 2018; Wagner et al., 2018). Brown et al. surveyed GCs 
about their genesurance practices and identified that 99% of clinical GCs spend some time on 
discussing genesurance during a clinical appointment, and the majority feel like it is important 
(87%) and a part of their job description (85%) (Brown et al., 2018). Relatedly, Wagner et al. 
surveyed patients on their expectation of a GC’s role regarding genesurance (Wagner et al., 2018). 
The study identified the majority of patients expect GCs to provide an estimated out-of-pocket 
expense (78%), know if a test is a covered benefit (77%), and to discuss this information during 
the appointment (75%) (Wagner et al., 2018). However, the multitude of insurance plans, various 
contracts with laboratories, thousands of genetic testing options, and inconsistent CPT® coding 
makes this a difficult task. Further, other medical providers do not typically go into the same detail 
of insurance coverage as GCs (Hooker et al., 2018). 
5.1.2 Overview of Medical Coding 
Insurance coverage for healthcare services is dictated by two coding systems: the World 
Health Organization’s (WHO’s) International Classification of Diseases (ICD) and US’s Current 
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Procedural Terminology (CPT®). The ICD code is the patient’s diagnosis and the CPT® code is 
the procedure or service rendered.  
5.1.2.1 ICD Coding 
The ICD coding system was developed in 1893 when the International Statistical Institute 
charged a committee to create an international medical coding system to understand the 
epidemiology and statistics in deaths (Moriyama et al., 2011). The first iteration of ICD codes was 
known as the International List of Causes of Death and was rapidly adapted by many European 
and North American countries (Moriyama et al., 2011). These codes have been updated 
approximately every ten years, reflective of the latest understanding of medical diagnoses. The 
sixth iteration, ICD-6, entailed two major revisions with the addition of morbidity (medical 
diagnoses throughout life) instead of just mortality (causes of death) and changing the 
responsibility to maintain the coding from the United Nations to the World Health Organization 
(WHO) (Moriyama et al., 2011). Another major change occurred with the advent of ICD-10. 
Instead of utilizing a number-only organization system, ICD-10 utilizes an alpha numeric 
organization scheme to classify the body location, manifestation, and etiology of the disease, 
where the letter represents the body system, and the numbers denote details of the disease; this 
system allows for 14,000 different codes to exist, with further modifications by individual 
countries allowing for even more codes (Moriyama et al., 2011).  
The WHO heeds users that ICD diagnosis codes are suitable for statistical and 
epidemiological studies, not billing purposes (World Health Organization, 1989). The U.S. 
realized that while ICD codes were useful for epidemiologic monitoring, they were lacking in 
clinical needs of the current billing structure of insurance. To address this need, the National Center 
for Health Statistics and the Council on Clinical Classifications joined forces to develop clinical 
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modifications (CM) to the ICD-9 scheme, creating ICD-9-CM (National Center for Health 
Statistics and Health Care Financing Administration, 1979). The clinical modifications allow for 
additional use of medical coding, including “indexing of medical records, medical care review, 
and ambulatory and other medical care programs” (National Center for Health Statistics and Health 
Care Financing Administration, 1979). Other countries have made similar modifications to reflect 
their need for medical record indexing and reimbursement (Moriyama et al., 2011). 
Iterations of ICD-10 are currently in use, as it was released in the early 1990s (World 
Health Organization, 1989). The U.S. adopted ICD-10 for its death certificates in 1999; however, 
ICD-10 was not implemented in the U.S. until clinical modifications were complete to create the 
ICD-10-CM diagnosis coding (Center for Disease Control and Prevention, n.d.). The transition 
from ICD-9-CM to ICD-10-CM was required for U.S. Health Insurance Portability and 
Accountability Act (HIPAA) healthcare providers by October 1, 2015, after four years of 
postponement (Center for Disease Control and Prevention, n.d.; Health and Human Services, 
2009). Additionally, there was the creation procedure coding system (PCS) modifications, ICD-
10-PCS, for inpatient procedures (Center for Disease Control and Prevention, n.d.). The latest 
edition of ICD diagnosis coding, ICD-11, was developed in June 2018 with plans of 
implementation in June 2022 (World Health Organization, n.d.). 
5.1.2.2 CPT® Coding 
Similar to ICD coding, CPT® coding had origins other than medical billing. A review of 
CPT® coding was written by Dotson, but is also reviewed in this document (Dotson, 2013). In 
1966, the American Medical Association (AMA) developed CPT® coding as a shorthand way to 
denote procedures performed, mainly surgeries, in the patient’s medical record (American Medical 
Association, n.d.). In the 1970s, these codes were updated to reflect other procedures and 
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implemented the five-digit numerical code still used today. CPT® codes were adopted for billing 
purposes in 1983 when Centers for Medicare and Medicaid Services (CMS) wanted to replace 
their billing code system of Healthcare Common Procedure Coding System (HCPCS) with CPT® 
billing codes for Medicare Part B claims (American Medical Association, n.d.). Throughout the 
1980s, CPT® billing codes were adapted for Medicaid claims and outpatient surgical procedures, 
and the coding system was adapted by all HIPAA healthcare providers by October 2003 (American 
Medical Association, n.d.). 
Currently, there are about 10,000 CPT® codes, and they are reviewed three times a year by 
the CPT® Editorial Panel, consisting of 17 doctors and experts from the AMA and other relevant 
organizations; during this process, codes are updated, removed, and added (American Medical 
Association, 2014). New codes suggested by healthcare providers, professional societies, or other 
parties are considered for addition, and the process from proposal to implementation takes 
approximately two to three years (American Medical Association, 2013; CPT® Editorial Panel, 
n.d.).  
There are four main categories of CPT® codes: Category I, Category II, Category III, and 
Proprietary Laboratory Analyses (PLA) codes (CPT®, 2018). Category I codes consist of 
established procedures, such as surgeries, lab work, or radiology. Category II codes are 
supplemental tracking codes and are optional and used for quality measurements instead of billing 
purposes. Category III codes are for new procedures that do not quite meet Category I criteria and 
are tracked for assessment and outcomes of the procedure. Finally, PLA codes are a recent addition 
to the CPT® codes; PLAs are CPT® codes for proprietary procedures performed by a single source 
or multiple licensed facilities for tests such as genetic testing, advanced diagnostic laboratory tests, 
and clinical diagnostic laboratory tests (CPT®, 2018).  
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While insurance companies have a variety of services they will cover, the patient’s ICD 
diagnosis needs to match the CPT® services provided. For example, a patient with acute 
appendicitis without abscesses, ICD-10-CM code K35.20, would undergo an appendectomy, 
CPT® code 44950; however, if a patient’s medical record was coded with the diagnosis of 
unspecified abdominal pain, R10.9, an appendectomy would not be covered, as the diagnosis code 
does not reflect an appropriate reason as to why the appendix was removed. For genetics, ICD-10-
CM code F82, denoting developmental delay, would be an appropriate diagnosis to undergo a SNP 
chromosomal microarray, CPT® code 81229, according to some payer coverage policies.  
5.1.2.3 CPT® Coding for Genetic Testing 
Accurate CPT® coding for genetic testing is complicated by there being over 75,000 
genetic tests and approximately only 200 genetic testing specific CPT® codes (Concert Genetics, 
2018; CPT®, 2018). Historically, genetic testing was coded on what was being performed on the 
sample – cell lysing, DNA extraction, PCR, interpretation, etc. The problem with this system was 
two-fold. First, different labs have different procedures for the same test, causing a different 
number of codes to be billed for. Using Medicare’s Clinical Laboratory Fee Schedule, a lab’s 
combination of CPT® codes for a 32-mutation CFTR analysis could cost anywhere from $180.22 
to $516.22 due to the possible variations in coding and reimbursement (Logue, 2003). A similar, 
but not as disparate, analysis was also reported for KRAS assessment (Carlson, 2010). The second 
problem was that insurance companies did not know what they were paying for; all other 
laboratory CPT® codes were specific enough to allow the insurer to understand what was 
specifically performed. Many organizations, including the Department of Health and Human 
Services and AMP, recognized this coding problem, and the AMA developed a new, analyte-
specific, two tier system for genetic testing CPT® codes (Association for Molecular Pathology, 
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2009; CPT®, 2018; S. Wright, 2012). Within Category I are two tiers of codes for genetic testing 
and molecular pathology (MoPath Codes). Tier I provides codes for testing of single genes or 
commonly ordered tests and Tier II includes catchall codes based on complexity of the test, ranging 
from identifying a single nucleotide variant to assessing 50 or more exons.  
While each of the Tier I codes can only be billed once, Tier II codes and the miscellaneous 
81479 code can be billed for multiple times with the use of modifiers. For example, 81479x4 
means that code is performed (and billed) four times. Therefore, a genetic test can have multiple, 
separate Tier I codes and multiple Tier II and 81479 codes (with or without modifiers).  
As with all CPT® codes, some modifications of genetic-specific codes have been made, 
and Table 7 represents a sample of current (as of May 2019), commonly used genetic testing CPT® 
codes.  
 
Table 7. Examples of genetic testing specific CPT® codes  
CPT® code Descriptor 
Tier I: Single Gene 
81220 CFTR common variants (e.g., ACMG/ACOG guidelines)  
81221 CFTR known familial variants  
81222 CFTR duplication/deletion variants  
81223 CFTR full gene sequence  
81224 CFTR intron 8 poly-T analysis  
81243  FMR1 evaluation to detect abnormal (e.g., expanded) alleles  
81244 FMR1 characterization of alleles (e.g., expanded size and promoter methylation 
status) 
Tier I: Multigene 
81228  Cytogenomic microarray analysis; interrogation of genomic regions for copy 
number variants  
81229 Cytogenomic microarray analysis; interrogation of genomic regions for copy 
number variants and SNP  
81415 Exome sequence analysis  
81416 Exome sequence analysis, each comparator exome (e.g., parents, siblings)  
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81425 Genome sequence analysis 
81460 Whole mitochondrial genome sequencing, including heteroplasmy detection  
81465 Whole mitochondrial genome large deletion analysis panel, including heteroplasmy 
detection 
81440 Nuclear encoded mitochondrial genes sequence panel, must include analysis of at 
least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, 
OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, 
SUCLG1, TAZ, TK2, and TYMP 
81410 Aortic dysfunction or dilation genomic sequence analysis panel, must include 
sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, 
MYH11, ACTA2, SLC2A10, SMAD3, and MYLK  
81411 Aortic dysfunction or dilation duplication/deletion analysis panel, must include 
analyses for TGFBR1, TGFBR2, MYH11, and COL3A1  
81413 Cardiac ion channelopathies genomic sequence analysis panel, must include 
sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, 
KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A 
81414 Cardiac ion channelopathies duplication/deletion gene analysis panel, must include 
analysis of at least 2 genes, including KCNH2 and KCNQ1  
81439 Hereditary cardiomyopathy sequence analysis panel, must include sequencing of at 
least 5 cardiomyopathy related genes  
81430 Hearing loss sequence analysis panel, must include sequencing of at least 60 genes, 
including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, 
PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and 
WFS1  
81431 Hearing loss duplication/deletion analysis panel, must include copy number 
analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes 
81442 Noonan spectrum disorders sequence analysis panel, must include sequencing of at 
least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, 
NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1 
81470 X-linked intellectual disability sequence analysis panel, must include sequencing of 
at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, 
IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and 
SLC16A2  
81471 X-linked intellectual disability duplication/deletion gene analysis, must include 
analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, 
HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, 
RPS6KA3, and SLC16A2  
Tier II: Miscellaneous  
81400  Molecular pathology procedure, Level 1 analysis  
81401 Molecular pathology procedure, Level 2 analysis  
81402  Molecular pathology procedure, Level 3 analysis  
81403  Molecular pathology procedure, Level 4 analysis  
Table 7 Continued 
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81404  Molecular pathology procedure, Level 5 analysis  
81405  Molecular pathology procedure, Level 6 analysis  
81406  Molecular pathology procedure, Level 7 analysis  
81407  Molecular pathology procedure, Level 8 analysis  
81408  Molecular pathology procedure, Level 9 analysis  
81479  Unlisted molecular pathology procedure 
Adapted from (American Medical Association, 2018) 
  
While these specific CPT® codes exist, there is room for interpretation by the genetic 
testing laboratory on how they denote their testing options. A health policy expert noted that 
comprehensive BRCA1/2 sequencing, deletion/duplication, and rearrangement testing can be 
coded three ways, to lead to three different CMS reimbursement charges; however, these 
reimbursement rates vary by contracts and fee schedules (Quinn, 2017). The first, most intuitive 
way, uses the comprehensive code 81162 with a charge of $1,615; however, the charge can be 
increased to $2,948 using codes 81211 (BRCA1/2 sequencing and deletion/duplication) and 81213 
(uncommon deletion/duplications) or lowered to $813 using codes 81214 (BRCA1 sequencing and 
deletion/duplication), 81216 (BRCA2 sequencing and deletion/duplication), and 81213 (Quinn, 
2017). In a webinar, Dunn, a GC with an insurance company, argues that while panels do cost less 
from a technology perspective, they often cost more due to coding inefficiencies (Hooker et al., 
2018). 
Furthermore, there are problems with the 81479 code and the tier II codes. Tier II codes, 
including the miscellaneous 81479, lack the specificity of what test is actually performed to 
accurately bill for these services. While these codes were created with the intent to increase 
transparency on what is test is performed, there are currently no guidelines on how to code for 
multigene panels. This leaves the interpretation to the individual labs, which causes many 
Table 7 Continued 
 103 
differences in coding for similar multigene panels. However, despite what coding the laboratory 
selects, the billing entity can modify which codes they chose to bill for through insurance.  
5.1.3 Review of Epilepsy and Genetics 
Epilepsy is a relatively common neurological condition, with a lifetime prevalence of 7.6 
per 1,000 individuals worldwide (Fiest et al., 2017), affecting approximately 3.5 million 
individuals in the U.S. (Center for Disease Control and Prevention, 2019). The International 
League Against Epilepsy (ILAE) defines epilepsy as “a disease of the brain defined by any of the 
following conditions: at least two unprovoked (or reflex) seizures occurring greater than 24 hours 
apart; one unprovoked (or reflex) seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next ten years; or 
diagnosis of an epilepsy syndrome” in 2014 (Fisher et al., 2014). In 2017, ILAE updated their 
operational classification of seizures: seizures can be either focal onset, generalized onset, or 
unknown onset; can be motor (ex. tonic-clonic) or non-motor (ex. absence); and can impair 
awareness or not (Fisher et al., 2017). Additionally, ILAE recognizes six different etiologic 
categories of epilepsy, of which multiple can be explanatory of a patient’s epilepsy (Falco-Walter 
et al., 2018). Epilepsy can be caused by a structural aberration, a genetic explanation, an infection, 
metabolic derangement, auto-immune disease, unknown, or a combination of these (Falco-Walter 
et al., 2018). 
Many review articles on genetics and epilepsy are present in the literature and are discussed 
in this paper (El Achkar et al., 2015; Hildebrand et al., 2013; Pal et al., 2010; Poduri et al., 2014; 
Ream & Patel, 2015; Sands & Choi, 2017; Sisodiya, 2015; Thomas & Berkovic, 2014). 
 104 
Historically, most epilepsy was considered idiopathic; however, recent advances in 
genetics has elucidated the role of single gene disorders, chromosomal aberrations, and 
polygenetic risk factors as a significant portion of causes of epilepsy. While the epidemiology of 
genetic-caused epilepsy is not exactly known, it is estimated that approximately one-third of 
epilepsy diagnoses have a strong genetic component, with another one-quarter of diagnoses having 
modifier and susceptibility alleles as contributing factors (Thomas & Berkovic, 2014). Genetics 
has a stronger likelihood to be contributory to a patient’s epilepsy if there is a family history of 
seizures, younger age of onset, more severe presentation, certain brain MRI findings, and if other 
causes, such as infection, auto-immune disease, and trauma, are ruled out (Berg et al., 2017; Lindy 
et al., 2018; Sands & Choi, 2017). Additionally, these factors can guide the differential diagnosis 
and genetic testing selection. However, family history assessment of epilepsy and development of 
a differential diagnosis is complicated by genetic and phenotypic heterogeneity, reduced 
penetrance, variable expressivity, and de novo variants. SCN1A is the most common genetic cause 
of epilepsy, and accounts for a spectrum of different epilepsy conditions, including generalized 
epilepsy with febrile seizures plus (GEFS+), intractable childhood epilepsy with generalized tonic-
clonic seizures (ICE-GTC), intractable infantile partial seizures, myoclonic astatic epilepsy 
(MAE), severe myoclonic epilepsy in infancy (SMEI) or Dravet Syndrome (DS), and simple 
febrile seizures (I. Miller & Sotero de Menezes, 2019). Some of the more common genetic epilepsy 
conditions are presented in Table 8. 
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Table 8. Common genetic epilepsy syndromes  
Gene(s)/chromosomal region* Name of Condition 
15q11-q13, UBE3 Angelman Syndrome 
1p36  Chromosome 1p36 deletion syndrome 
CHD2, GABRA1, HCN1, 
PCDH19, SCN1A, SCN1B , 
SCN9A, STXBP1  
Dravet Syndrome 
ARX, CDKL5, KCNQ2, 
SLC25A22, STXBP1 
Early infantile epileptic encephalopathy 
SCN1A, SCN9A Generalized epilepsy with febrile seizure plus (GEFS+) 
SLC2A1 Glucose transporter type 1 deficiency syndrome 
17p13.3 Miller-Dieker Syndrome 
MECP2 Rett Syndrome 
Chromosome 20 Ring chromosome 20 
TSC1, TSC2  Tuberous Sclerosis Complex 
Adapted from (El Achkar et al., 2015; Hildebrand et al., 2013; Lindy et al., 2018; Pal et al., 2010; Poduri et al., 
2014; Ream & Patel, 2015; Thomas & Berkovic, 2014) 
*Genes may be listed multiple times due to the genetic heterogeneity of having multiple associated conditions 
 
5.1.3.1 Multigene Epilepsy Panels 
Currently, there are no professional guidelines on genetic testing for epilepsy, but literature 
suggests comprehensive, multi-gene epilepsy panels are an appropriate first-tier test for many 
individuals who have a diagnosis of epilepsy (Berg et al., 2017; Levenson, 2017; Lindy et al., 
2018). Comprehensive, multi-gene epilepsy panels are beneficial as they have a relatively high 
diagnostic yield, are able to assess many genetic epilepsy conditions, and may lead to actionable 
results.  
In one genetic testing laboratory, patients with epilepsy received a genetic diagnosis 15.4% 
(1315/8565) of the time (Lindy et al., 2018). Of these genetic explanations, the majority (90%) 
were due to a sequencing change while only 9% were due to a copy number variant (Lindy et al., 
2018). A prospective observational study of children with Early-Life Epilepsy (epilepsy diagnosed 
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before the age of 3) found epilepsy panels had higher diagnostic yield (27%, 31/114) compared to 
chromosomal microarrays (17%, 32/188) (Berg et al., 2017). While whole exome sequencing does 
have a higher diagnostic yield (33%, 11/33) (Berg et al., 2017), another study found that due to 
the high cost of exomes, epilepsy panels have the best cost-effective diagnostic yield (Sanchez 
Fernandez et al., 2019). The cost-benefit analysis also indicated that chromosomal microarrays 
would be the best cost-effective diagnostic yield if it costs less than $1,267 (Sanchez Fernandez et 
al., 2019). Alternatively, if the patient has epilepsy and intellectual disability, developmental delay, 
multiple congenital anomalies, or dysmorphic features, a chromosomal microarray may have better 
diagnostic yield compared to a multi-gene epilepsy panel, but the cost-effectiveness was not 
studied (El Achkar et al., 2015; D. T. Miller et al., 2010).  
Epilepsy is a condition with significant genetic and phenotypic heterogeneity. Even if the 
epilepsy syndrome fits a certain phenotype, such as infantile epilepsy, the patient may have a 
genetic diagnosis in a gene not traditionally associated with their presentation of symptoms. 
Additionally, the NGS platform allows for moderately sized panels to have a similar cost to larger 
panels. Therefore, more genes can be assessed and more actionable differential diagnoses can be 
ruled in or out, thus guiding management. A possible drawback to a broader panel, however, is a 
higher likelihood of receiving a VUS. 
Finally, understanding if epilepsy has a genetic etiology can guide treatment and 
management, as some genes provide actionable results. For example, individuals with Glucose 
Transporter Deficiency Type I, caused by a pathogenic variant in SLC2A1, can often effectively 
manage their seizures and other manifestations with a ketogenic diet (Klepper et al., 2005); 
individuals with Pyridoxine-Dependent Epilepsy, caused by biallelic pathogenic variants in 
ALDH7A1, are treated with pyridoxine supplements (Basura et al., 2009); and individuals with 
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certain POLG pathogenic variants should avoid valproic acid as a seizure medication as it can 
cause liver disease or failure (Saneto et al., 2010). Additionally, if genetic test results do not yield 
a diagnosis, a provider is able to rule out many conditions that could have changed management.  
5.1.3.2 Call for Multigene Epilepsy Panel CPT® Coding 
Currently, there is no designated CPT® code for multi-gene epilepsy panels. Epilepsy, with 
a lifetime prevalence of 7.6 in 1000, is more common than cardiomyopathy (US prevalence 1 in 
500 adults), X-linked intellectual disability (prevalence 1 in 600 males), inherited arrythmias 
(prevalence 1 in 2000), and mitochondrial diseases (prevalence 1 in 5000 adults), which do have 
a panel specific CPT® code; therefore, it would be appropriate for epilepsy panels to have their 
own CPT® code (Center for Disease Control and Prevention, 2015; Fiest et al., 2017; McKenzie 
et al., 2016; Ng & Turnbull, 2016; P. J. Schwartz et al., 2009). Through creation of an epilepsy 
multi-gene panel CPT® code, standards for a minimum gene list would be established, insurance 
companies would have an accurate understanding of testing performed, laboratories would be able 
to more accurately bill for their services, and patient outcomes may improve. 
While insurance coverage for genetic CPT® codes varies significantly by plan, transparent 
coding with the creation of a multigene epilepsy sequencing panel CPT® code will allow for correct 
patient billing, accurate reimbursement, and create a standard for genetic testing laboratories. With 
thousands of different genetic tests, but only a couple hundred CPT® codes, it is impossible for 
consistent and customary billing (Concert Genetics, 2018; CPT®, 2018). This lack of transparency 
in CPT® coding may lead to insurance denying the test, causing the patient to either have a 
significant bill or not be able to access the service, or if the insurance approves the test, the 
insurance may over pay or under pay for the test due the lack of consistent CPT® codes. 
 108 
5.1.4 Specific Aims 
5.1.4.1 Specific Aim 1 
To determine CPT® coding and genes included on epilepsy sequencing panels at various genetic 
testing laboratories.  
5.1.4.2 Specific Aim 2 
To propose standards for CPT® coding for multigene epilepsy sequencing panels.  
5.2 Methods 
5.2.1 Current CPT® Coding of Epilepsy Multigene Sequencing Panels 
The current landscape of CPT® coding for epilepsy multigene sequencing panels at 
commercial genetic testing laboratories in the U.S. was assessed. Genetic testing laboratories 
included in this study were determined by search results identified via Concert Genetics (formerly 
NextGxDx), a website and technology company that assists with transparency and navigation of 
genetic testing (Concert Genetics, n.d.). Concert Genetics groups genetic tests by similar 
indications and if they are single-target or panel testing to allow for side-by-side comparisons 
(Concert Genetics, n.d.). Genetic tests listed in the category “Epilepsy and Seizure Disorder Panel 
Tests” were reviewed, and laboratories were included if they were commercial, U.S. based, and 
offered at least one epilepsy sequencing panels.  
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Once laboratories were identified, their websites were interrogated for their offerings of 
epilepsy sequencing panels. Tests were identified in two ways: the search box and 
neurology/epilepsy specific test menus. First, the words “epilepsy”, “epileptic”, and “seizure” were 
searched, and results were read to identify multigene sequencing panels with one of the 
aforementioned words in the test name. Similarly, if the laboratory website had a neurology 
specific or epilepsy specific test menu or webpage, the tests were read to identify multigene 
sequencing panels with one of the aforementioned words in the test name. Tests were excluded if 
they were offered on a research basis.  
Next, the test page was read to identify the genes included on the panel and the CPT® codes 
for the test. If the CPT® codes or gene lists were not available on the website, a phone call was 
made to the lab’s customer service to obtain this information.  
The variables, including lab, test, genes, and CPT® codes, were assessed using descriptive 
statistics to understand trends in multigene epilepsy sequencing panels. Statistical analyses were 
completed using GraphPad Prism (v. 8, San Diego, CA).  
5.2.2 Proposed CPT® Code for Epilepsy Multigene Sequencing Panels 
There is no background literature on how the minimum gene lists were determined for 
already established multigene panel CPT® codes. However, reasonable inclusion criteria for a 
minimum gene list are relatively common etiologies of genetic epilepsy and genes that have 
actionable results. Therefore, the inclusion criteria for the proposed CPT® Code for Epilepsy 
Multigene Sequencing Panels is represented in Table 9. The inclusion criteria were determined by 
reviewing the prevalence of genes included on current CPT® codes for multigene panels. A brief 
review of literature yielded most genes had a prevalence less than 1:100,000; however, some genes 
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were rarer, such as TAZ (1:140,000), HRAS (1:230,00), and WFS1 (1:550,000) (Abe et al., 2011; 
Barrett et al., 1995; Clarke et al., 2013). For epilepsy genes where prevalence was established, the 
prevalence was compared to the proportion of patients who had a pathogenic sequencing variant 
in a specific gene within a cohort of individuals with genetic epilepsy based on Lindy et al., which 
estimates 1:100,000 is approximately equal to 3% of patients with a pathogenic sequencing variant 
in a specific gene within a cohort of individuals with genetic epilepsy (Lindy et al., 2018). There 
is a genetic etiology for epilepsy approximately 25% of the time, which represents the 0.75% of 
patients with an epilepsy condition due to a pathogenic sequencing variant in a specific gene within 
a cohort of individuals with epilepsy. If a treatment was available, the criterion was scaled to 
include rarer genes.  
 A literature review for the prevalence and treatment of genetic epilepsy was performed. 
Genes that were identified to be present in 12 or more (20%) panels were investigated. Peer-
reviewed literature was read to determine the prevalence and specific treatment (if available) for 
each of the genes. Due to the possibility of isolated ethnic groups having a high prevalence due 
the founder effect, genes were included if the prevalence was determined in multiple ethnic groups 
or a multi-ethnic study. If there was no peer-reviewed literature on the gene’s prevalence it was 
excluded, as this likely represents a lower prevalence. It is possible for a gene to meet one criterion 
but fail another; these genes are included due to the ease of multigene sequencing on NGS 
platforms. The proposed minimum gene list for the CPT® code is based on the genes that met the 
inclusion criteria based on the literature review performed.  
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Table 9. Inclusion criteria of genes for proposed CPT® code for epilepsy multigene sequencing panel 
Inclusion criteria 
Prevalence of at least 1:100,000 of an epilepsy condition due to a pathogenic sequencing 
variant in a specific gene OR 
Prevalence of at least 1:150,000 of an epilepsy condition due to a pathogenic sequencing 
variant in a specific gene AND actionable results for treatment or agents to avoid OR 
Prevalence of at least 0.75% of an epilepsy condition due to a pathogenic sequencing variant 
in a specific gene within a cohort of individuals with epilepsy OR 
Prevalence of at least 0.5% of an epilepsy condition due to a pathogenic sequencing variant in 
a specific gene within a cohort of individuals with epilepsy AND actionable results for 
treatment or agents to avoid 
Prevalence of at least 3% of an epilepsy condition due to a pathogenic sequencing variant in a 
specific gene within a cohort of individuals with genetic epilepsy OR 
Prevalence of at least 2% of an epilepsy condition due to a pathogenic sequencing variant in a 
specific gene within a cohort of individuals with genetic epilepsy AND actionable results 
for treatment or agents to avoid 
 
5.3 Results 
5.3.1 Current CPT® Coding of Epilepsy Multigene Sequencing Panels 
Concert genetics identified 128 different genetic tests in the category “Epilepsy and Seizure 
Disorder Panel Tests”. These tests are offered by 27 different laboratories, of which eight were 
excluded. Four labs were excluded as they are passthrough laboratories, two labs were excluded 
as they are not commercially available, one was excluded as it was not US-based and one was 
excluded as it was Direct to Consumer testing. The remaining 19 labs were included in the analysis.  
These 19 labs offer 63 NGS-based multigene epilepsy panels, as outlined in Table 10. All 
the information was available online, with the exception of CPT® codes for five laboratories where 
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calls were made. Of note, all panels are unique, with the exception of an identical seven-gene 
epilepsy and migraine panel offered by two different laboratories; however, different CPT® coding 
was used.  
 
Table 10. Overview of dataset  
Variable n (standard deviation) [range] 
Labs 19 
Different panels 63 
Small panel (39 genes or less) 20 
Medium panel (40-99 genes) 20 
Large panel (100+ genes) 23 
Mean tests/lab 3.3 (2.5) [1-9] 
Mean number of genes on panel 129 (213) [7-1501] 
Mean number of CPT® codes/test 4.2 (3.4) [1-14] 
Mean number of Tier I codes/test 1.0 (0.2) [0-6] 
Mean number of Tier II codes/test 2.6 (2.8) [0-7] 
Mean number of 81479 codes/test 0.6 (0.5) [0-1] 
Mean number of genes/CPT® code 30.6 (92.5) [1.8-595] 
Mean number of CPT® modifiers/test 33.3 (105.8) [1-628] 
Mean number of Tier I modifiers/test 1.0 (1.4) [0-6] 
Mean number of Tier II modifiers/test 7.8 (15.2) [0-96] 
Mean number of 81479 modifiers/test 24.5 (92.7) [0-567] 
Mean number of genes/CPT® modifier 3.9 (90.6) [0.5-595] 
 
There were a total of 1577 different genes included on these panels. No gene was present 
in all panels, however, SCN1A, the most common genetic cause of epilepsy, was the most common 
gene in all the panels. Details of gene content in the panels is presented in Table 11. 
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 Table 11. Gene content in panels  
Count* Gene(s) 
50 SCN1A 
46 SLC2A1 
45 SCN2A 
44 FOLR1 
43 CDKL5, POLG 
42 GRIN2A, SCN1B 
41 KCNT1, PCDH19, STXBP1 
39 ALDH7A1, ARX, KCNQ2, MECP2, PNPO, SCN8A, TBC1D24 
38 GABRA1 
37 GABRG2, KCNQ3, KCTD7, PPT1 
36 CHD2, CLN3, CLN5, CLN6, CLN8, MEF2C, MFSD8, TPP1, TSC1, TSC2 
35 EPM2A, FOXG1, GABRB3, GAMT, NHLRC1, PRRT2, SPTAN1 
34 ADSL, CSTB, CTSD, GOSR2, PNKP, SLC25A22, SLC9A6 
33 CACNA1A 
32 ARHGEF9, CNTNAP2, ZEB2 
31 EEF1A2, GRIN2B, LGI1, MBD5, NRXN1, SCARB2, UBE3A 
30 CHRNA2, CHRNA4, CHRNB2, GRIN1, PLCB1, SLC6A8, SYNGAP1, TCF4, 
WDR45 
29 SLC19A3 
28 DNM1, GATM, SLC13A5 
27 CASK, KCNB1, PIGA, PRICKLE1, WWOX 
26 DEPDC5, GNAO1, HCN1, PURA, SCN9A, STX1B, SZT2 
25 ALG13, KCNJ10, SLC35A2 
24 ATP1A2, IQSEC2, KCNC1, ST3GAL5 
23 DYRK1A 
22 DNAJC5, KANSL1, PIGO, ST3GAL3 
21 ASAH1, EFHC1, GABRB2, GLDC, HNRNPU, SLC6A1, SMC1A, SYN1 
20 AMT, ATP6AP2, CLCN4, CTSF, FLNA, KCNA2 
 
*Genes that are on less than 20 different panels are not included in this table 
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Finally, laboratory-recommended CPT® codes varied drastically between panels. A full list 
of CPT® codes used is presented in Table 12.  
 
 Table 12. CPT® codes used  
CPT® Code CPT® Code Description Number of 
panels in 
which code 
was used 
Number of 
times code 
was used 
(modifiers) 
Tier I Codes  66 66 
81175 ASXL1 Full Sequencing 1 1 
81185 CACNA1A Full Sequencing 5 5 
81189 CSTB Full Sequencing 10 10 
81210 BRAF V600 Analysis 2 2 
81290 MCOLN1 Variant Analysis 1 1 
81291 MTHFR Variant Analysis 1 1 
81302 MECP2 Full Sequencing 14 14 
81304 MECP2 Deletion/Duplication Analysis 7 7 
81311 NRAS Variant Analysis 1 1 
81321 PTEN Full Sequencing 2 2 
81323 PTEN Deletion/Duplication Analysis 2 2 
81330 SMPD1 Variant Analysis 1 1 
81415 Exome Sequencing 1 1 
81443 Genetic testing for severe inherited conditions. 
Must include sequencing of at least 15 genes 15 15 
81460 Whole mitochondrial genome sequencing, with 
heteroplasmy detection 1 1 
81465 Whole mitochondrial genome large deletion 
analysis panel 1 1 
Tier II Codes  63 490 
81401 Level 2 analysis (eg, 2-10 SNPs, 1 methylated 
variant, or 1 somatic variant, or detection of a 
dynamic mutation disorder/triplet repeat) 4 7 
81403 Level 4 analysis (eg, analysis of single exon by 
DNA sequence analysis, analysis of > 10 
amplicons using multiplex PCR in 2 or more 
independent reactions, mutation scanning or 
duplication/deletion variants of 2-5 exons) 17 24 
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81404 Level 5 analysis (eg, analysis of 2-5 exons by DNA 
sequence analysis, mutation scanning or 
duplication/deletion variants of 6-10 exons, or 
characterization of a dynamic mutation 
disorder/triplet repeat by Southern blot 
analysis) 30 98 
81405 Level 6 analysis (eg, analysis of 6-10 exons by 
DNA sequence analysis, mutation scanning or 
duplication/ deletion variants of 11-25 exons) 34 125 
81406 Level 7 analysis (eg, analysis of 11-25 exons by 
DNA sequence analysis, mutation scanning or 
duplication/deletion variants of 26-50 exons, 
cytogenomic array analysis for neoplasia) 36 165 
81407 Level 8 analysis (eg, analysis of 26-50 exons by 
DNA sequence analysis, mutation scanning or 
duplication/ deletion variants of > 50 exons, 
sequence analysis of multiple genes on 1 
platform) 34 57 
81408 Level 9 analysis (eg, analysis of > 50 exons in a 
single gene by DNA sequence analysis) 8 14 
81479 Unlisted molecular pathology procedure 35 1544 
 
 
5.3.2 Proposed CPT® Code for Epilepsy Multigene Sequencing Panels 
Based on a review of the literature, 25 genes met the inclusion criteria for the proposed 
multigene epilepsy sequencing panel CPT® code: ALDH7A1, CACNA1A, CDKL5, CHD2, 
GABRG2, GLDC, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, 
SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2. 
However, the CPT® code could allow analysis of additional genes with the phrasing “must include 
sequencing of at least # genes, including…”. This list was determined based on the inclusion 
criteria in Table 9. The genes, condition, prevalence, and treatment are listed in Table 13.  
 
 
  
 
Table 12 Continued 
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Table 13. Proposed genes for multigene epilepsy sequencing panel CPT® code  
Gene Condition(s) Estimated Prevalence Specific 
Treatment 
ALDH7A1 Pyridoxine-Dependent Epilepsy 1:20,0001 – 1:100,0002 Pyridoxine3 
CACNA1A Early Infantile Epileptic 
Encephalopathy, Type 42 
0.9% of individuals with 
epilepsy4 
Acetazolamide5 
CDKL5 Early Infantile Epileptic 
Encephalopathy, Type 2 
7.6% of individuals with 
genetic epilepsy6; 1.8% 
of individuals with 
epilepsy4 
Ketogenic diet7 
CHD2 Childhood-onset Epileptic 
Encephalopathy 
1.2% of individuals with 
epilepsy8 
–* 
GABRG2 Generalized Epilepsy with Febrile 
Seizures Plus, Type 3; Early 
Infantile Epileptic 
Encephalopathy, Type 74; 
Familial Febrile Seizures, Type 8 
3.6% of individuals with 
genetic epilepsy6 
–* 
GLDC Glycine Encephalopathy 1:90,0009,10 Benzoate11-13, 
NMDA receptor 
antagonist11,12, 
low protein diet13; 
Avoid valproate14 
GRIN2A GRIN2A-Related Speech 
Disorders and Epilepsy 
2.4-3.2% of individuals 
with genetic epilepsy4,6 
Avoid 
carbamazepine, 
barbiturates, and 
phenytoin 15,16 
KCNQ2 Early Infantile Epileptic 
Encephalopathy, Type 7; Benign 
Neonatal Seizures, Type 1 
13.2% of individuals 
with genetic epilepsy6; 
1.8-2.9% of individuals 
with epilepsy4,17 
Lacosamide18 
MECP2 Rett Syndrome 3.5% of individuals with 
genetic epilepsy6 
–* 
PCDH19 Early Infantile Epileptic 
Encephalopathy, Type 9 
5.7% of individuals with 
genetic epilepsy6 0.9% of 
individuals with 
epilepsy6 
–* 
POLG Alpers-Huttenlocher syndrome; 
Childhood 
myocerebrohepatopathy spectrum; 
Myoclonic epilepsy myopathy 
sensory ataxia 
1:51,00019 Avoid valproic 
acid20 
PRRT2 Familial Infantile Convulsions 
with Paroxysmal Choreoathetosis; 
7.2% of individuals with 
genetic epilepsy6 
–* 
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Benign Familial Infantile 
Seizures, Type 2 
SCN1A Dravet syndrome; Generalized 
epilepsy with febrile seizures plus; 
Intractable childhood epilepsy 
with generalized tonic-clonic 
seizures; Intractable infantile 
partial seizures; Myoclonic astatic 
epilepsy; Simple febrile seizures 
1:15,00021 – 1:41,00022; 
24.8% of individuals 
with genetic epilepsy6; 
3.6-4.4% of individuals 
with epilepsy4,17 
Avoid 
carbamazepine23, 
lamotrigine24, 
vigabatrin25, and 
phenytoin26  
SCN1B Generalized Epilepsy with Febrile 
Seizures Plus, type 1; Early 
Infantile Epileptic 
Encephalopathy, Type 52 
1.2% of individuals with 
epilepsy4 
–* 
SCN2A Early Infantile Epileptic 
Encephalopathy, Type 11; Benign 
Familial Infantile Seizures, Type 3 
7.4% of individuals with 
genetic epilepsy6; 1.8% 
of individuals with 
epilepsy4,17 
Sodium channel 
blocker if seizures 
before 3 months27 
SCN8A Early Infantile Epileptic 
Encephalopathy, Type 13; Benign 
Familial Infantile Seizures, Type 5 
3.6% of individuals with 
genetic epilepsy6; 1.5% 
of individuals with 
epilepsy4 
–* 
SLC2A1 Glucose Transporter Type I 
Deficiency Syndrome 
1:83,00028 – 1:90,00029; 
3.2-3.6% of individuals 
with genetic epilepsy4,6 
Ketogenic diet30 
SLC9A6 Christianson Syndrome 1:16,000 – 1:100,00031 –* 
STXBP1 STXBP1 Encephalopathy with 
Epilepsy 
1:91,00032; 5.1% of 
individuals with genetic 
epilepsy6; 1.2-2.7% of 
ividuals with epilepsy4,17 
–* 
SYNGAP1 SYNGAP1-Related Developmental 
and Epileptic Encephalopathy 
1.0% of individuals with 
epilepsy10 
–* 
TCF4 Pitt-Hopkins Syndrome 1:11,00033 – 1:41,00034 –* 
TPP1 Neuronal Ceroid Lipofuscinosis, 
Type 2 
0.9% of individuals with 
epilepsy4 
–* 
TSC1 Tuberous Sclerosis Complex 1:120,00035-37 Vigabatrin38  
TSC2 Tuberous Sclerosis Complex 1:43,00035-37; 2.3-3.2% 
of individuals with 
genetic epilepsy4,6 
Vigabatrin38 
ZEB2 Mowat-Wilson Syndrome 1:50,000 – 1:70,00039 –* 
 
References: 1. (Ebinger et al., 1999) 2. (Baxter et al., 1996) 3. (Basura et al., 2009) 4. (Butler et al., 2017) 5. (Battistini 
et al., 1999) 6. (Lindy et al., 2018) 7. (Lim et al., 2017) 8. (Carvill et al., 2013) 9. (Applegarth et al., 2000) 10. (Kure 
et al., 2006) 11. (Bjoraker et al., 2016) 12. (Korman et al., 2004) 13. (Hennermann et al., 2012) 14. (Hall & Ringel, 
2004) 15. (Striano & Capovilla, 2013) 16. (Van Bogaert, 2013) 17. (Mercimek-Mahmutoglu et al., 2015) 18. 
(Schubert-Bast et al., 2017) 19. (Darin et al., 2001) 20. (Saneto et al., 2010) 21. (Wu et al., 2015) 22. (Brunklaus et 
al., 2012) 23. (Horn et al., 1986) 24. (Guerrini et al., 1998) 25. (Ceulemans et al., 2004) 26. (Saito et al., 2001) 27. 
Table 13 Continued 
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(Wolff et al., 2017) 28. (Larsen et al., 2015) 29. (Coman et al., 2006) 30. (Klepper et al., 2005) 31. (Pescosolido et al., 
2014) 32. (Stamberger et al., 2016) 33. (Whalen et al., 2012) 34. (Rosenfeld et al., 2009) 35. (Osborne et al., 1991) 
36. (Jones et al., 1999) 37. (Au et al., 2007) 38. (Camposano et al., 2008) 39. (Mowat & Wilson, 2010) 
* Peer reviewed literature search did not yield a specific treatment of choice  
 
5.4 Discussion 
5.4.1 Current CPT® Coding of Epilepsy Multigene Sequencing Panels 
There is significant variety in content of multigene epilepsy sequencing panels, as well as 
significant variety in CPT® coding.  
First, panels varied in gene content, ranging from as small as seven genes, to over 1500 
genes. Panels were often divided into phenotypes, such as comprehensive testing, infantile 
epilepsy, childhood onset epilepsy, epileptic encephalopathy, epilepsy with migraines, myoclonic 
epilepsy, febrile epilepsy, focal epilepsy, and panels with actionable genes. Given the clinical and 
genetic heterogeneity of genetic epilepsy, though, it can be difficult to properly assess and 
diagnosis patients especially early on in their disease presentation when full symptomatology may 
not have completely evolved.  
While common genes were noted in similar panels, only one set of panels had identical 
genes - an epilepsy with migraine panel; however, one lab only coded the panel with only one 
CPT® code, while the other lab coded the panel with six CPT® codes. This difference in coding of 
the same panel content is reflective of the highly variable interpretation of CPT® coding.  
Other laboratories also differed in their interpretation of CPT® codes. PreventionGenetics 
has a 2:1 ratio of CPT® codes to gene, while Knight Molecular Diagnostics has a 1:1 ratio. All 
other labs tended to assign CPT® codes based on the analysis performed at large, instead of a gene 
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by gene approach. Through this approach, some labs had as few as one CPT® code per test, often 
using 81443 (genetic testing for severe inherited conditions) or 81479 (unlisted molecular 
pathology procedure). However, the AMA is working on a platform to provide clarity and 
recommended coding on a test by test basis (J. Vento, personal communication, June 3, 2019).  
5.4.2 Proposed CPT® Code for Epilepsy Multigene Sequencing Panels 
The review of literature for prevalence and treatment yielded 25 genes that met the criteria 
for the proposed CPT® code for epilepsy multigene sequencing panels. Already established CPT® 
codes for panel gene coverage requirements vary from as few as two genes for cardiac ion 
channelopathies duplication/deletion gene analysis panel to as many as 19 specific genes with 
analysis of at least 100 genes for a nuclear encoded mitochondrial genes sequence panel (American 
Medical Association, 2018). While the proposed 25 specific genes for an epilepsy multigene 
sequence CPT® code is more than what is required in already established CPT® codes, this more 
extensive gene requirement is potentially needed to account for the significant genetic 
heterogeneity of epilepsy.  
The inclusion criteria for the genes was specifically based on the prevalence of an “epilepsy 
condition due to a pathogenic sequencing variant in a specific gene” as this CPT® code is for 
epilepsy multigene sequencing panels. A pathogenic sequencing variant accounts for about 90% 
of all epilepsies with a genetic etiology, with the remaining 10% due to a pathogenic copy number 
variant (CNV) or an imprinting aberration (Lindy et al., 2018). Of note, UBE3A, the gene 
associated with Angelman Syndrome, was excluded from the proposed gene list. While Angelman 
Syndrome has a high enough prevalence of 1:12,000 – 1:50,000, only 11% of Angelman Syndrome 
diagnoses are due to a sequencing variant (the majority are due to a methylation aberration which 
 120 
cannot be identified on an NGS platform) (Fang et al., 1999; Malzac et al., 1998; Oiglane-Shlik et 
al., 2006; Steffenburg et al., 1996). Therefore, calculations estimate the prevalence of UBE3A 
pathogenic sequencing variants at about 1:109,000 – 1:455,000, which is not a high enough 
prevalence to justify its inclusion on the gene list.  
5.4.3 Limitations  
5.4.3.1 Current CPT® Coding of Epilepsy Multigene Sequencing Panels 
The data collected for the current CPT® coding of epilepsy multigene sequencing panels is 
accurate as of May 2019; however, labs may change their CPT® codes at any time.  
While differences in genetic testing laboratory CPT® coding practices were elucidated, the 
downstream effects of these differences on insurance company coverage and reimbursement and 
patient outcomes were not assessed. There is little public transparency by insurance companies on 
coverage of services. Furthermore, coverage of services varies significantly by insurance plan. 
Additionally, reimbursement is affected by contracts insurance companies have with different 
laboratories. Due to these complexities, cost and other related outcomes were not assessed.  
Finally, epilepsy multigene sequencing panels are not the only genetic test that has 
inconsistent CPT® coding. These nuances in coding are present in other genetic tests but were not 
assessed as it would be beyond the scope of this project. Future projects should assess these 
nuances and propose standardized CPT® coding to increase consistency and improve transparency.  
5.4.3.2 Proposed CPT® Code for Epilepsy Multigene Sequencing Panels 
There are no evidence-based guidelines on how to determine a minimum gene list for a 
CPT® code. As such, an important limitation of this project was that this was an academic exercise 
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that did not account for expert opinion, which would be necessary before finalization of a proposed 
gene list. A reasonable guideline, though, is a relatively high prevalence of a pathogenic variant in 
genes associated with epilepsy with special considerations for genes that have actionability. 
Further consideration and literature review would need to be completed to identify additional genes 
that should be included on a proposed panel. Due to genetic conditions being rare, prevalence of 
these conditions can be estimated within a degree of magnitude, but accurate, specific prevalence 
rate is difficult to calculate. Therefore, it is likely that genes were included when the true 
prevalence of pathogenic sequencing variants is lower than the cutoff and that genes were excluded 
when the true prevalence of pathogenic sequencing variants is higher than the cutoff. As such, this 
proposed gene list should be used as a starting point for future work on developing a final minimum 
gene list for a CPT® code. 
Additionally, the inclusion criteria were only based on the prevalence of conditions caused 
by a pathogenic sequencing variant that include an epilepsy phenotype. Given the variable 
expressivity of genetic conditions, a condition may have epilepsy as a phenotypic outcome in only 
a minority of cases. For example, TCF4 was included on the gene list, but only about one-third of 
patients with Pitt-Hopkins Syndrome have epilepsy (de Winter et al., 2016). Future analyses 
should include the likelihood of epilepsy for each condition and could be considered for 
development of gene lists for CPT® codes.  
As we understand more of prevalence of these conditions and the prevalence of epilepsy 
within these conditions, the gene list for all CPT® codes should be updated. 
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5.5 Conclusion 
There are substantial differences in CPT® coding for multigene epilepsy sequencing panels. 
The lack of consistency affects laboratory reimbursement, insurance coverage, and patient care. 
Therefore, clear CPT® coding is imperative. The proposed gene list would provide a standard of 
care for multigene epilepsy sequencing panels and allow for more transparency for all 
stakeholders. This has public health significance as epilepsy affects millions of Americans and 
there is benefit of understanding the possible genetic role in the etiology of epilepsy for care and 
management. Therefore, it is imperative to provide access to more uniform genetic testing with 
consistent, transparent CPT® coding.  
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